<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd"><coredata><prism:url>http://api.elsevier.com/content/article/pii/S0168365913003295</prism:url><dc:identifier>doi:10.1016/j.jconrel.2013.05.037</dc:identifier><eid>1-s2.0-S0168365913003295</eid><prism:doi>10.1016/j.jconrel.2013.05.037</prism:doi><pii>S0168-3659(13)00329-5</pii><dc:title>In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes </dc:title><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:aggregationType>Journal</prism:aggregationType><prism:issn>01683659</prism:issn><prism:volume>172</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>426</prism:startingPage><prism:endingPage>435</prism:endingPage><prism:pageRange>426-435</prism:pageRange><prism:number>2</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2013-12-10</prism:coverDate><prism:coverDisplayDate>10 December 2013</prism:coverDisplayDate><prism:copyright>Copyright © 2013 The Authors. Published by Elsevier B.V.</prism:copyright><prism:publisher>The Authors. Published by Elsevier B.V.</prism:publisher><prism:issueName>Proceedings of the Sixteenth International Symposium on Recent Advances in Drug Delivery Systems</prism:issueName><dc:creator>Zheng, Yiran</dc:creator><dc:creator>Stephan, Matthias T.</dc:creator><dc:creator>Gai, S. Annie</dc:creator><dc:creator>Abraham, Wuhbet</dc:creator><dc:creator>Shearer, Adrianne</dc:creator><dc:creator>Irvine, Darrell J.</dc:creator><dc:description>AbstractIn adoptive cell therapy (ACT), autologous tumor-specific T-cells isolated from cancer patients are activated and expanded ex vivo, then infused back into the individual to eliminate metastatic tumors. A major limitation of this promising approach is the rapid loss of ACT T-cell effector function in vivo due to the highly immunosuppressive environment in tumors. Protection of T-cells from immunosuppressive signals can be achieved by systemic administration of supporting adjuvant drugs such as interleukins, chemotherapy, and other immunomodulators, but these adjuvant treatments are often accompanied by serious toxicities and may still fail to optimally stimulate lymphocytes in all tumor and lymphoid compartments. Here we propose a novel strategy to repeatedly stimulate or track ACT T-cells, using cytokines or ACT-cell-specific antibodies as ligands to target PEGylated liposomes to transferred T-cells in vivo. Using F(ab′)2 fragments against a unique cell surface antigen on ACT cells (Thy1.1) or an engineered interleukin-2 (IL-2) molecule on an Fc framework as targeting ligands, we demonstrate that &gt;95% of ACT cells can be conjugated with liposomes following a single injection in vivo. Further, we show that IL-2-conjugated liposomes both target ACT cells and are capable of inducing repeated waves of ACT T-cell proliferation in tumor-bearing mice. These results demonstrate the feasibility of repeated functional targeting of T-cells in vivo, which will enable delivery of imaging contrast agents, immunomodulators, or chemotherapy agents in adoptive cell therapy regimens.</dc:description><openaccess>1</openaccess><openaccessArticle>true</openaccessArticle><openaccessType>Full</openaccessType><openArchiveArticle>false</openArchiveArticle><openaccessSponsorName/><openaccessSponsorType>ElsevierWaived</openaccessSponsorType><openaccessUserLicense>http://creativecommons.org/licenses/by-nc-sa/3.0/</openaccessUserLicense><dcterms:subject>Immunoliposomes</dcterms:subject><dcterms:subject>Interleukin-2 (IL-2)</dcterms:subject><dcterms:subject>Cancer immunotherapy</dcterms:subject><dcterms:subject>Adoptive cell therapy</dcterms:subject><dcterms:subject>Targeted delivery</dcterms:subject><dcterms:subject>Melanoma</dcterms:subject><link rel="self" href="http://api.elsevier.com/content/article/pii/S0168365913003295"/><link rel="scidir" href="http://www.sciencedirect.com/science/article/pii/S0168365913003295"/></coredata><objects><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3148" height="4116" size="1513017">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3148" height="4291" size="937343">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1212" height="2522" size="316114">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3147" height="4296" size="1028798">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1474" height="4279" size="386841">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="825" size="325773">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="930" size="195996">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="969" size="136687">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="273" height="568" size="35476">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="711" height="971" size="146864">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="333" height="967" size="61411">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="186" size="44255">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="125" height="163" size="9203">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="120" height="164" size="4560">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="78" height="162" size="3444">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="120" height="164" size="4361">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="56" height="163" size="1945">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="82" size="6248">http://api.elsevier.com/content/object/eid/1-s2.0-S0168365913003295-fx1.sml?httpAccept=%2A%2F%2A</object></objects><scopus-id>84887121506</scopus-id><scopus-eid>2-s2.0-84887121506</scopus-eid><pubmed-id>23770010</pubmed-id><link rel="abstract" href="http://api.elsevier.com/content/abstract/scopus_id/84887121506"/><originalText><xocs:doc xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://be-prod3a/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>271103</xocs:cid><xocs:ssids><xocs:ssid type="alllist">291210</xocs:ssid><xocs:ssid type="subj">291681</xocs:ssid><xocs:ssid type="subj">291789</xocs:ssid><xocs:ssid type="content">31</xocs:ssid><xocs:ssid type="oa">90</xocs:ssid></xocs:ssids><xocs:srctitle>Journal of Controlled Release</xocs:srctitle><xocs:normalized-srctitle>JOURNALCONTROLLEDRELEASE</xocs:normalized-srctitle><xocs:orig-load-date yyyymmdd="20130611">2013-06-11</xocs:orig-load-date><xocs:available-online-date yyyymmdd="20130611">2013-06-11</xocs:available-online-date><xocs:ew-transaction-id>2014-09-20T20:41:45</xocs:ew-transaction-id><xocs:eid>1-s2.0-S0168365913003295</xocs:eid><xocs:pii-formatted>S0168-3659(13)00329-5</xocs:pii-formatted><xocs:pii-unformatted>S0168365913003295</xocs:pii-unformatted><xocs:doi>10.1016/j.jconrel.2013.05.037</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.3</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S0168365913X00197</xocs:hub-eid><xocs:timestamp yyyymmdd="20150514">2015-05-14T05:17:02.743021-04:00</xocs:timestamp><xocs:dco>0</xocs:dco><xocs:tomb>0</xocs:tomb><xocs:date-search-begin>20131210</xocs:date-search-begin><xocs:year-nav>2013</xocs:year-nav><xocs:indexeddate epoch="1370908800">2013-06-11T00:00:00Z</xocs:indexeddate><xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids confeditor contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid fundingbodyid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight oauserlicense openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sortorder sponsoredaccesstype srctitle srctitlenorm srctype ssids alllist content oa subj subheadings tomb vol volfirst volissue volumelist webpdf webpdfpagecount yearnav figure body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor primabst ref specialabst</xocs:articleinfo><xocs:issns><xocs:issn-primary-formatted>0168-3659</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>01683659</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:crossmark is-crossmark="1">true</xocs:crossmark><xocs:vol-first>172</xocs:vol-first><xocs:volume-list><xocs:volume>172</xocs:volume></xocs:volume-list><xocs:iss-first>2</xocs:iss-first><xocs:issue-list><xocs:issue>2</xocs:issue></xocs:issue-list><xocs:vol-iss-suppl-text>Volume 172, Issue 2</xocs:vol-iss-suppl-text><xocs:sort-order>8</xocs:sort-order><xocs:first-fp>426</xocs:first-fp><xocs:last-lp>435</xocs:last-lp><xocs:pages><xocs:first-page>426</xocs:first-page><xocs:last-page>435</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>20131210</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>10 December 2013</xocs:cover-date-text><xocs:cover-date-start>2013-12-10</xocs:cover-date-start><xocs:cover-date-year>2013</xocs:cover-date-year><xocs:title-editors-groups><xocs:title-editors-group><ce:title>Proceedings of the Sixteenth International Symposium on Recent Advances in Drug Delivery Systems</ce:title><ce:editors><ce:author-group><ce:author><ce:given-name>You Han</ce:given-name><ce:surname>Bae</ce:surname></ce:author></ce:author-group><ce:author-group><ce:author><ce:given-name>David W.</ce:given-name><ce:surname>Grainger</ce:surname></ce:author></ce:author-group><ce:author-group><ce:author><ce:given-name>Wim E.</ce:given-name><ce:surname>Hennink</ce:surname></ce:author></ce:author-group></ce:editors></xocs:title-editors-group></xocs:title-editors-groups><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2013 The Authors. Published by Elsevier B.V.</xocs:copyright-line><xocs:normalized-article-title>INVIVOTARGETINGADOPTIVELYTRANSFERREDTCELLSANTIBODYCYTOKINECONJUGATEDLIPOSOMES</xocs:normalized-article-title><xocs:normalized-first-auth-surname>ZHENG</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>Y</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>1</xocs:item-toc-label><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2</xocs:item-toc-label><xocs:item-toc-section-title>Material and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.1</xocs:item-toc-label><xocs:item-toc-section-title>Materials</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.2</xocs:item-toc-label><xocs:item-toc-section-title>Preparation of IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf></xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.3</xocs:item-toc-label><xocs:item-toc-section-title>Synthesis of IL-2-Fc-liposomes and anti-Thy1.1-liposomes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.4</xocs:item-toc-label><xocs:item-toc-section-title>Quantification of targeting ligands coupled to liposomes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.5</xocs:item-toc-label><xocs:item-toc-section-title>Activation of pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup>CD8<ce:sup loc="post">+</ce:sup> T-cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.6</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vitro</ce:italic> liposome binding to T-cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.7</xocs:item-toc-label><xocs:item-toc-section-title>Titration of liposome concentration for <ce:italic>in vitro</ce:italic> conjugation</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.8</xocs:item-toc-label><xocs:item-toc-section-title>Internalization of liposomes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.9</xocs:item-toc-label><xocs:item-toc-section-title>Adoptive transfer and <ce:italic>in vivo</ce:italic> liposome targeting</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.10</xocs:item-toc-label><xocs:item-toc-section-title>Adoptive transfer of CBR-Luc T-cells and bioluminescence imaging</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.11</xocs:item-toc-label><xocs:item-toc-section-title>Sample preparation for flow cytometry</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>2.12</xocs:item-toc-label><xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3</xocs:item-toc-label><xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.1</xocs:item-toc-label><xocs:item-toc-section-title>Synthesis and characterization of IL-2-Fc-Lip and anti-Thy1.1-Lip</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.2</xocs:item-toc-label><xocs:item-toc-section-title>IL-2-Fc-Lip and anti-Thy1.1-Lip binding to T-cells <ce:italic>in vitro</ce:italic></xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.3</xocs:item-toc-label><xocs:item-toc-section-title>Internalization of Anti-Thy1.1-conjugated liposomes</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.4</xocs:item-toc-label><xocs:item-toc-section-title><ce:italic>In vivo</ce:italic> targeting of IL-2-Fc-Lip and anti-Thy1.1-Lip in healthy animals</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>3.5</xocs:item-toc-label><xocs:item-toc-section-title>IL-2-Fc-Lip permit repeated boosting of ACT T-cells in a murine lung metastasis model</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-label>4</xocs:item-toc-label><xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>MELLMAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>480</xocs:ref-first-fp><xocs:ref-last-lp>489</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>TOPALIAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>2443</xocs:ref-first-fp><xocs:ref-last-lp>2454</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>KALOS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>95ra73</xocs:ref-first-fp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>ROSENBERG</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>4550</xocs:ref-first-fp><xocs:ref-last-lp>4557</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>YEE</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>16168</xocs:ref-first-fp><xocs:ref-last-lp>16173</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>MORGAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>126</xocs:ref-first-fp><xocs:ref-last-lp>129</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>RESTIFO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>269</xocs:ref-first-fp><xocs:ref-last-lp>281</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>BESSER</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>2646</xocs:ref-first-fp><xocs:ref-last-lp>2655</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>RUBINSTEIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>700</xocs:ref-first-fp><xocs:ref-last-lp>707</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>PRIETO</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>547</xocs:ref-first-fp><xocs:ref-last-lp>556</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>KOBAYASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1075</xocs:ref-first-fp><xocs:ref-last-lp>1084</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>MARKLEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>3508</xocs:ref-first-fp><xocs:ref-last-lp>3519</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>KERKAR</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>6725</xocs:ref-first-fp><xocs:ref-last-lp>6734</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>HSU</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>5168</xocs:ref-first-fp><xocs:ref-last-lp>5177</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>STEPHAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>1035</xocs:ref-first-fp><xocs:ref-last-lp>1041</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>STEPHAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>5776</xocs:ref-first-fp><xocs:ref-last-lp>5787</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>FAHMY</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>75</xocs:ref-first-fp><xocs:ref-last-lp>85</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>TSAI</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>568</xocs:ref-first-fp><xocs:ref-last-lp>580</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>CLEMENTECASARES</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>733</xocs:ref-first-fp><xocs:ref-last-lp>742</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>1255</xocs:ref-first-fp><xocs:ref-last-lp>1263</xocs:ref-last-lp><xocs:ref-normalized-initial>X</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>KALOS</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>138</xocs:ref-first-fp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>MINAMI</xocs:ref-normalized-surname><xocs:ref-pub-year>1993</xocs:ref-pub-year><xocs:ref-first-fp>245</xocs:ref-first-fp><xocs:ref-last-lp>268</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>KWONG</xocs:ref-normalized-surname><xocs:ref-pub-year>2013</xocs:ref-pub-year><xocs:ref-first-fp>1547</xocs:ref-first-fp><xocs:ref-last-lp>1558</xocs:ref-last-lp><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>BAUDINO</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>6664</xocs:ref-first-fp><xocs:ref-last-lp>6669</xocs:ref-last-lp><xocs:ref-normalized-initial>L</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>OVERWIJK</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>569</xocs:ref-first-fp><xocs:ref-last-lp>580</xocs:ref-last-lp><xocs:ref-normalized-initial>W</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>LOWENTHAL</xocs:ref-normalized-surname><xocs:ref-pub-year>1985</xocs:ref-pub-year><xocs:ref-first-fp>3988</xocs:ref-first-fp><xocs:ref-last-lp>3994</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>LOWENTHAL</xocs:ref-normalized-surname><xocs:ref-pub-year>1985</xocs:ref-pub-year><xocs:ref-first-fp>669</xocs:ref-first-fp><xocs:ref-last-lp>672</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>KWONG</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-normalized-initial>B</xocs:ref-normalized-initial><xocs:ref-normalized-srctitle>BIOLOGICALENGINEERING</xocs:ref-normalized-srctitle><xocs:ref-normalized-article-title>LIPOSOMEANCHOREDLOCALDELIVERYIMMUNOMODULATORYAGENTSFORTUMORTHERAPY</xocs:ref-normalized-article-title></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>MURPHY</xocs:ref-normalized-surname><xocs:ref-pub-year>1984</xocs:ref-pub-year><xocs:ref-first-fp>1757</xocs:ref-first-fp><xocs:ref-last-lp>1762</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>KLEBANOFF</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>111</xocs:ref-first-fp><xocs:ref-last-lp>117</xocs:ref-last-lp><xocs:ref-normalized-initial>C</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>DUDLEY</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>243</xocs:ref-first-fp><xocs:ref-last-lp>251</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>KONRAD</xocs:ref-normalized-surname><xocs:ref-pub-year>1990</xocs:ref-pub-year><xocs:ref-first-fp>2009</xocs:ref-first-fp><xocs:ref-last-lp>2017</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:refkeys><xocs:refkey3>ZHENGX2013X426</xocs:refkey3><xocs:refkey4lp>ZHENGX2013X426X435</xocs:refkey4lp><xocs:refkey4ai>ZHENGX2013X426XY</xocs:refkey4ai><xocs:refkey5>ZHENGX2013X426X435XY</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2013-07-16T20:15:39Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>ElsevierWaived</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by-nc-sa/3.0/</xocs:oa-user-license></xocs:open-access><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S0168-3659(13)00329-5</xocs:pii-formatted><xocs:pii-unformatted>S0168365913003295</xocs:pii-unformatted><xocs:eid>1-s2.0-S0168365913003295</xocs:eid><xocs:doi>10.1016/j.jconrel.2013.05.037</xocs:doi><xocs:cid>271103</xocs:cid><xocs:timestamp>2014-09-21T04:22:47.830453-04:00</xocs:timestamp><xocs:cover-date-start>2013-12-10</xocs:cover-date-start><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S0168365913003295-main.pdf</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/MAIN/application/pdf/a86d4aaab951363e60ddb12e3e6287fc/main.pdf</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/MAIN/application/pdf/a86d4aaab951363e60ddb12e3e6287fc/main.pdf</xocs:ucs-locator><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>1595686</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>10</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S0168365913003295-main_1.png</xocs:attachment-eid><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/PREVIEW/image/png/3de23de3ab53768d4ff4e97e92e95f6b/main_1.png</xocs:ucs-locator><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/PREVIEW/image/png/3de23de3ab53768d4ff4e97e92e95f6b/main_1.png</xocs:ucs-locator><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>54974</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr5_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr5/HIGHRES/image/jpeg/ebbc1b73d572e98e5700edf3becb6faf/gr5_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr5/HIGHRES/image/jpeg/ebbc1b73d572e98e5700edf3becb6faf/gr5_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>1513017</xocs:filesize><xocs:pixel-height>4116</xocs:pixel-height><xocs:pixel-width>3148</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr4_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr4/HIGHRES/image/jpeg/c4378b6774cf36d22a1a6f9a5612cc3d/gr4_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr4/HIGHRES/image/jpeg/c4378b6774cf36d22a1a6f9a5612cc3d/gr4_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>937343</xocs:filesize><xocs:pixel-height>4291</xocs:pixel-height><xocs:pixel-width>3148</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr3_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr3/HIGHRES/image/jpeg/5f90c2ffdb95dc918912bcd80e461781/gr3_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr3/HIGHRES/image/jpeg/5f90c2ffdb95dc918912bcd80e461781/gr3_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>316114</xocs:filesize><xocs:pixel-height>2522</xocs:pixel-height><xocs:pixel-width>1212</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr2_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr2/HIGHRES/image/jpeg/cd695075108fc82deab587fd59541ef9/gr2_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr2/HIGHRES/image/jpeg/cd695075108fc82deab587fd59541ef9/gr2_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>1028798</xocs:filesize><xocs:pixel-height>4296</xocs:pixel-height><xocs:pixel-width>3147</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr1/HIGHRES/image/jpeg/030930ccaefa01742dfab702c8d879b2/gr1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr1/HIGHRES/image/jpeg/030930ccaefa01742dfab702c8d879b2/gr1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>386841</xocs:filesize><xocs:pixel-height>4279</xocs:pixel-height><xocs:pixel-width>1474</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-fx1_lrg.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/fx1/HIGHRES/image/jpeg/dd3b70bd4e3209edefc9455d38459666/fx1_lrg.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/fx1/HIGHRES/image/jpeg/dd3b70bd4e3209edefc9455d38459666/fx1_lrg.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>325773</xocs:filesize><xocs:pixel-height>825</xocs:pixel-height><xocs:pixel-width>2213</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr5.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr5/DOWNSAMPLED/image/jpeg/cdbfe1066834d49b349530f752bbdb94/gr5.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr5/DOWNSAMPLED/image/jpeg/cdbfe1066834d49b349530f752bbdb94/gr5.jpg</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>195996</xocs:filesize><xocs:pixel-height>930</xocs:pixel-height><xocs:pixel-width>711</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr4.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr4/DOWNSAMPLED/image/jpeg/7792114a97e3d492a8f4f97e982e9f1c/gr4.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr4/DOWNSAMPLED/image/jpeg/7792114a97e3d492a8f4f97e982e9f1c/gr4.jpg</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>136687</xocs:filesize><xocs:pixel-height>969</xocs:pixel-height><xocs:pixel-width>711</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr3.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr3/DOWNSAMPLED/image/jpeg/7cb94449c584fb80f6111f4494086104/gr3.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr3/DOWNSAMPLED/image/jpeg/7cb94449c584fb80f6111f4494086104/gr3.jpg</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>35476</xocs:filesize><xocs:pixel-height>568</xocs:pixel-height><xocs:pixel-width>273</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr2.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr2/DOWNSAMPLED/image/jpeg/4070d6ac2ccce10b4bb8e6e6fc378c66/gr2.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr2/DOWNSAMPLED/image/jpeg/4070d6ac2ccce10b4bb8e6e6fc378c66/gr2.jpg</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>146864</xocs:filesize><xocs:pixel-height>971</xocs:pixel-height><xocs:pixel-width>711</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr1/DOWNSAMPLED/image/jpeg/be4b3be3e0c9378755b96e518a128aaa/gr1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr1/DOWNSAMPLED/image/jpeg/be4b3be3e0c9378755b96e518a128aaa/gr1.jpg</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>61411</xocs:filesize><xocs:pixel-height>967</xocs:pixel-height><xocs:pixel-width>333</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-fx1.jpg</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/fx1/DOWNSAMPLED/image/jpeg/a4f05d3e9a8eaac525b262267a97d968/fx1.jpg</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/fx1/DOWNSAMPLED/image/jpeg/a4f05d3e9a8eaac525b262267a97d968/fx1.jpg</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>44255</xocs:filesize><xocs:pixel-height>186</xocs:pixel-height><xocs:pixel-width>500</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr5.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr5/THUMBNAIL/image/gif/6bffcefc1dcf8973cf929fab9c9b0ce6/gr5.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr5/THUMBNAIL/image/gif/6bffcefc1dcf8973cf929fab9c9b0ce6/gr5.sml</xocs:ucs-locator><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>9203</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>125</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr4.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr4/THUMBNAIL/image/gif/fa58e78b546d6a60ab7fbd978ced95b4/gr4.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr4/THUMBNAIL/image/gif/fa58e78b546d6a60ab7fbd978ced95b4/gr4.sml</xocs:ucs-locator><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>4560</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>120</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr3.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr3/THUMBNAIL/image/gif/b139dd05dc46492e7f4e3d649ee60183/gr3.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr3/THUMBNAIL/image/gif/b139dd05dc46492e7f4e3d649ee60183/gr3.sml</xocs:ucs-locator><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>3444</xocs:filesize><xocs:pixel-height>162</xocs:pixel-height><xocs:pixel-width>78</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr2.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr2/THUMBNAIL/image/gif/ff351ff3d2bb929abccb65b2d744d008/gr2.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr2/THUMBNAIL/image/gif/ff351ff3d2bb929abccb65b2d744d008/gr2.sml</xocs:ucs-locator><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>4361</xocs:filesize><xocs:pixel-height>164</xocs:pixel-height><xocs:pixel-width>120</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-gr1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/gr1/THUMBNAIL/image/gif/b0cfc4f37425946c5f725b57641f4b51/gr1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/gr1/THUMBNAIL/image/gif/b0cfc4f37425946c5f725b57641f4b51/gr1.sml</xocs:ucs-locator><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>1945</xocs:filesize><xocs:pixel-height>163</xocs:pixel-height><xocs:pixel-width>56</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S0168365913003295-fx1.sml</xocs:attachment-eid><xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0168365913003295/fx1/THUMBNAIL/image/gif/d4d7330872d319aa920d8ff5ee51c2e7/fx1.sml</xocs:ucs-locator><xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0168365913003295/fx1/THUMBNAIL/image/gif/d4d7330872d319aa920d8ff5ee51c2e7/fx1.sml</xocs:ucs-locator><xocs:file-basename>fx1</xocs:file-basename><xocs:abstract-attachment>true</xocs:abstract-attachment><xocs:filename>fx1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>6248</xocs:filesize><xocs:pixel-height>82</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc></xocs:meta><xocs:serial-item><article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>COREL</jid><aid>6751</aid><ce:pii>S0168-3659(13)00329-5</ce:pii><ce:doi>10.1016/j.jconrel.2013.05.037</ce:doi><ce:copyright type="other" year="2013">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="f0010"><ce:label>Fig. 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0010" view="all">T-cell-targeted liposome synthesis and characterization. (A) Schematic of immunoliposome preparation. (B) Typical particle size distributions for liposomes before antibody conjugation (open bars) and after conjugation (black filled bars) determined by dynamic light scattering. (C) Quantification of ligand (IL-2 cytokine equivalent or anti-Thy1.1) coupled to liposomes incorporating different mole fractions of maleimide-PEG lipid: 2.5% (black filled bar), 1% (open bar) or 0% (striped bar), assessed by IL-2 ELISA and measuring FITC-labeled anti-Thy1.1 incorporation respectively.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0015"><ce:label>Fig. 2</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0015" view="all"><ce:italic>In vitro</ce:italic> binding of IL-2-Fc-Lip and anti-thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf>-Lip to primary T-cells. (A) Flow cytometry analysis of cell surface expression of CD25 and Thy1.1 on naïve C57BL6/J (Thy1.1<ce:sup loc="post">-</ce:sup>) splenocytes <ce:italic>vs.</ce:italic> activated pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup>CD8<ce:sup loc="post">+</ce:sup> T-cells. (B, C) Pmel-1 CD8<ce:sup loc="post">+</ce:sup> Thy1.1<ce:sup loc="post">+</ce:sup> T-cells were incubated with 0.7<ce:hsp sp="0.25"/>mg/ml (per 15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> cells) DiD-labeled liposomes (IL-2-Fc or anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> conjugated) for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C in complete RPMI, then analyzed by flow cytometry for liposome binding. Shown are representative flow cytometry scatter plots (B) and quantification of Mean Fluorescence Intensity (MFI) of pmel-1 T-cells as a function of mol% of mal-PEG-DSPE included in the vesicles (C). (D, E) Activated pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells were mixed with naive C57BL/6 splenocytes in a 1:1 ratio and incubated with 0.07<ce:hsp sp="0.25"/>mg/ml IL2-Fc-Lip or 0.15<ce:hsp sp="0.25"/>mg/ml anti-Thy1.1-Lip for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C, then analyzed by flow cytometry. (D) Shown are scatter plots representing liposome fluorescence on naive C57BL/6 CD8<ce:sup loc="post">+</ce:sup> T cells (Thy1.1<ce:sup loc="post">−</ce:sup>) and activated pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells (Thy1.1<ce:sup loc="post">+</ce:sup>) with/without 0.24<ce:hsp sp="0.25"/>mg/ml soluble IL2-Fc or 1.34<ce:hsp sp="0.25"/>mg/ml anti-Thy1.1 antibody added for 30<ce:hsp sp="0.25"/>min prior to addition of liposomes. Cells incubated with 0.15<ce:hsp sp="0.25"/>mg/ml IgG2a-lipo are also shown. (E) Quantification of the MFI of Pmel-1 CD8<ce:sup loc="post">+</ce:sup> T cells when bound with respective liposomes or pre-blocked by free Ab/IL-2. (F) Titrated concentrations of fluorescent liposomes were added to 5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 T-cells and incubated at 37<ce:hsp sp="0.25"/>°C for 30<ce:hsp sp="0.25"/>min, then analyzed by flow cytometry for MFI of T-cell-associated liposomes. *, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; ***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0020"><ce:label>Fig. 3</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" view="all">Internalization of Thy1.1-targeted liposomes. Carboxy-fluorescein (CF)-labeled anti-Thy1.1-Lip (1.4<ce:hsp sp="0.25"/>mg/ml) were incubated with 12<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells in 500<ce:hsp sp="0.25"/>μl RPMI containing 10% FCS for 1<ce:hsp sp="0.25"/>h at 4<ce:hsp sp="0.25"/>°C, washed, then incubated in RPMI at 37<ce:hsp sp="0.25"/>°C until analysis by flow cytometry 2<ce:hsp sp="0.25"/>h, 4<ce:hsp sp="0.25"/>h or 6<ce:hsp sp="0.25"/>h later. (A) MFI of T-cell-associated CF fluorescence. (B) Confocal images of cells at time zero or after 6<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C. Scale bar<ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>20<ce:hsp sp="0.25"/>μm.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 4</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" view="all">IL-2-Fc- and anti-Thy1.1-Liposomes target transferred T-cells <ce:italic>in vivo</ce:italic>. C57Bl/6 mice received i.v. adoptive transfer of 15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> pmel-1 CD8<ce:sup loc="post">+</ce:sup>Thy1.1<ce:sup loc="post">+</ce:sup> T-cells, followed by i.v. injection of 1.4<ce:hsp sp="0.25"/>mg IL-2-Fc-Lip, anti-Thy1.1-Lip, or isotype control IgG<ce:inf loc="post">2a</ce:inf>-Lip either immediately after the T-cells or 3<ce:hsp sp="0.25"/>days after the T-cells. Liposome binding to cells recovered from lymphoid organs and blood was analyzed 24<ce:hsp sp="0.25"/>h after liposome injections by flow cytometry. (A) Timeline of injections and analysis. (B) Representative flow cytometry plots illustrating gating strategy for analysis of liposome binding to transferred pmel-1 T-cells or endogenous CD8<ce:sup loc="post">+</ce:sup> T-cells. (C) Representative histograms of pmel-1 T-cell or endogenous CD8<ce:sup loc="post">+</ce:sup> T-cell labeling following day 0 liposome injections. (D–F) Quantification of percentages of endogenous or transferred T-cells labeled by day 0 or day 3 liposome injections in the blood (D), lymph nodes (E), and spleen (F). <ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>5 animals/group for IgG<ce:inf loc="post">2a</ce:inf>-Lip and anti-Thy1.1-Lip and <ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3 for IL-2-Fc-Lip. *, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01; ***, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001.</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 5</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0030" view="all">IL-2-Fc-liposomes allow repeated expansion of target ACT T-cells <ce:italic>in vivo</ce:italic> in tumor-bearing animals. (A–C) B16F10 tumor cells (1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup>) were injected i.v. into albino C57Bl/6 mice and allowed to establish lung metastases for 7<ce:hsp sp="0.25"/>days. Animals were then sublethally lymphodepleted by irradiation and received i.v. adoptive transfer of 12<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> luciferase-expressing pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells the next day. One group of mice additionally received injections of IL-2-Fc-Lip (1<ce:hsp sp="0.25"/>mg, carrying 60<ce:hsp sp="0.25"/>μg IL-2-Fc or 20<ce:hsp sp="0.25"/>μg IL-2 cytokine equivalent) i.v. immediately after T-cell transfer and again on day 6. (A) Timelines of cell/liposome injections and bioluminescence imaging of T-cells. (B) Representative bioluminescent images of ACT T-cells over time. (C) Quantification of average whole-body T-cell bioluminescence over time. (D–E) Groups of C57B/6 mice with established lung metastases were left untreated or were treated with T-cells as in A, then received either IL-2-Fc-Lip or equivalent total doses of systemic free IL-2 (10<ce:hsp sp="0.25"/>μg day 0, 20<ce:hsp sp="0.25"/>μg day 6) injected i.v. on day 0 and day 6. (D) Sample flow cytometry analyses showing percentages of tumor-specific (vβ13 TCR<ce:sup loc="post">+</ce:sup>) CD8<ce:sup loc="post">+</ce:sup> T-cells among T-cells in inguinal lymph nodes on day 12 after adoptive transfer. (E) Quantification of average frequency of tumor-specific (vβ13 TCR<ce:sup loc="post">+</ce:sup>) CD8<ce:sup loc="post">+</ce:sup> T-cells in inguinal lymph nodes 12<ce:hsp sp="0.25"/>days after adoptive transfer. <ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3–4 animals/group. *, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05; **, p<ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.01.</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure></ce:floats><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para id="np0005" view="all">This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.</ce:note-para></ce:article-footnote><ce:title id="ti0005"><ce:italic>In vivo</ce:italic> targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Yiran</ce:given-name><ce:surname>Zheng</ce:surname><ce:cross-ref refid="af0005" id="cf0005"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0010"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0010"><ce:given-name>Matthias T.</ce:given-name><ce:surname>Stephan</ce:surname><ce:cross-ref refid="af0010" id="cf0015"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="af0015" id="cf0020"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0015"><ce:given-name>S. Annie</ce:given-name><ce:surname>Gai</ce:surname><ce:cross-ref refid="af0010" id="cf0025"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="af0020" id="cf0030"><ce:sup loc="post">d</ce:sup></ce:cross-ref></ce:author><ce:author id="au0020"><ce:given-name>Wuhbet</ce:given-name><ce:surname>Abraham</ce:surname><ce:cross-ref refid="af0010" id="cf0035"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0025"><ce:given-name>Adrianne</ce:given-name><ce:surname>Shearer</ce:surname><ce:cross-ref refid="af0005" id="cf0040"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0030"><ce:given-name>Darrell J.</ce:given-name><ce:surname>Irvine</ce:surname><ce:cross-ref refid="af0005" id="cf0045"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0050"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="af0015" id="cf0055"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="af0025" id="cf0060"><ce:sup loc="post">e</ce:sup></ce:cross-ref><ce:cross-ref refid="af0030" id="cf0065"><ce:sup loc="post">f</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0070"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">djirvine@mit.edu</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, USA</ce:textfn><sa:affiliation><sa:organization>Department of Biological Engineering</sa:organization><sa:organization>Massachusetts Institute of Technology (MIT)</sa:organization><sa:city>Cambridge</sa:city><sa:state>MA</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Koch Institute for Integrative Cancer Research, MIT, Cambridge, USA</ce:textfn><sa:affiliation><sa:organization>Koch Institute for Integrative Cancer Research</sa:organization><sa:organization>MIT</sa:organization><sa:city>Cambridge</sa:city><sa:state>MA</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">Department of Material Science and Engineering, MIT, Cambridge, USA</ce:textfn><sa:affiliation><sa:organization>Department of Material Science and Engineering</sa:organization><sa:organization>MIT</sa:organization><sa:city>Cambridge</sa:city><sa:state>MA</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0020"><ce:label>d</ce:label><ce:textfn id="tn0020">Department of Chemical Engineering, MIT, Cambridge, USA</ce:textfn><sa:affiliation><sa:organization>Department of Chemical Engineering</sa:organization><sa:organization>MIT</sa:organization><sa:city>Cambridge</sa:city><sa:state>MA</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0025"><ce:label>e</ce:label><ce:textfn id="tn0025">Ragon Institute of Massachusetts General Hospital, MIT and Harvard University, Boston, USA</ce:textfn><sa:affiliation><sa:organization>Ragon Institute of Massachusetts General Hospital, MIT and Harvard University</sa:organization><sa:city>Boston</sa:city><sa:state>MA</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0030"><ce:label>f</ce:label><ce:textfn id="tn0030">Howard Hughes Medical Institute, Chevy Chase, USA</ce:textfn><sa:affiliation><sa:organization>Howard Hughes Medical Institute</sa:organization><sa:city>Chevy Chase</sa:city><sa:state>MD</sa:state><sa:country>USA</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Corresponding author at: MIT Room 76-261, 77 Massachusetts Avenue, Cambridge, MA 02139, USA. Tel.: +<ce:hsp sp="0.10"/>1 617 452 4174; fax: +<ce:hsp sp="0.10"/>1 617 452 3293.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="6" month="2" year="2013"/><ce:date-accepted day="20" month="5" year="2013"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">In adoptive cell therapy (ACT), autologous tumor-specific T-cells isolated from cancer patients are activated and expanded <ce:italic>ex vivo</ce:italic>, then infused back into the individual to eliminate metastatic tumors. A major limitation of this promising approach is the rapid loss of ACT T-cell effector function <ce:italic>in vivo</ce:italic> due to the highly immunosuppressive environment in tumors. Protection of T-cells from immunosuppressive signals can be achieved by systemic administration of supporting adjuvant drugs such as interleukins, chemotherapy, and other immunomodulators, but these adjuvant treatments are often accompanied by serious toxicities and may still fail to optimally stimulate lymphocytes in all tumor and lymphoid compartments. Here we propose a novel strategy to repeatedly stimulate or track ACT T-cells, using cytokines or ACT-cell-specific antibodies as ligands to target PEGylated liposomes to transferred T-cells <ce:italic>in vivo</ce:italic>. Using F(ab′)<ce:inf loc="post">2</ce:inf> fragments against a unique cell surface antigen on ACT cells (Thy1.1) or an engineered interleukin-2 (IL-2) molecule on an Fc framework as targeting ligands, we demonstrate that &gt;<ce:hsp sp="0.10"/>95% of ACT cells can be conjugated with liposomes following a single injection <ce:italic>in vivo</ce:italic>. Further, we show that IL-2-conjugated liposomes both target ACT cells and are capable of inducing repeated waves of ACT T-cell proliferation in tumor-bearing mice. These results demonstrate the feasibility of repeated functional targeting of T-cells <ce:italic>in vivo</ce:italic>, which will enable delivery of imaging contrast agents, immunomodulators, or chemotherapy agents in adoptive cell therapy regimens.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="graphical" id="ab0010" view="all"><ce:section-title id="st0010">Graphical abstract</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0035" view="all"><ce:display><ce:figure id="f0005"><ce:link locator="fx1" id="lk0030"/></ce:figure></ce:display></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" view="all" class="keyword"><ce:section-title id="st0015">Keywords</ce:section-title><ce:keyword id="kw0035"><ce:text id="tx0010">Immunoliposomes</ce:text></ce:keyword><ce:keyword id="kw0040"><ce:text id="tx0015">Interleukin-2 (IL-2)</ce:text></ce:keyword><ce:keyword id="kw0045"><ce:text id="tx0020">Cancer immunotherapy</ce:text></ce:keyword><ce:keyword id="kw0050"><ce:text id="tx0025">Adoptive cell therapy</ce:text></ce:keyword><ce:keyword id="kw0055"><ce:text id="tx0030">Targeted delivery</ce:text></ce:keyword><ce:keyword id="kw0060"><ce:text id="tx0035">Melanoma</ce:text></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:label>1</ce:label><ce:section-title id="st0020">Introduction</ce:section-title><ce:para id="p0005" view="all">Immunotherapy treatments stimulating a patient's own immune system to attack tumors are beginning to show signs of clinical efficacy, demonstrating that the immune system can be harnessed for cancer therapy even in patients with advanced disease <ce:cross-refs refid="bb0005 bb0010 bb0015" id="cf0075">[1–3]</ce:cross-refs>. Among many immunotherapy strategies in development, adoptive cell therapy (ACT) with autologous tumor-specific T-cells has shown particularly striking results in recent phase I clinical trials <ce:cross-refs refid="bb0015 bb0020" id="cf0080">[3,4]</ce:cross-refs>. In this approach, autologous T-cells isolated from tumor biopsies or peripheral blood are treated with cytokine/stimulatory cocktails to promote expansion of large numbers of tumor-reactive cells that can be reinfused into the patient, following which the transferred cells can home to disseminated tumor sites and destroy metastatic tumors. ACT therapy using completely autologous patient-derived tumor-infiltrating lymphocytes <ce:cross-refs refid="bb0020 bb0025" id="cf0085">[4,5]</ce:cross-refs> or patient T-cells transduced with genetically engineered T-cell receptors <ce:cross-refs refid="bb0015 bb0030" id="cf0090">[3,6]</ce:cross-refs> (TCRs, either exogenous TCR chains or chimeric antigen receptors composed of synthetic antigen-binding Ig domains fused with TCR signaling components) have been demonstrated to elicit objective response rates in up to 70% of patients with advanced metastatic melanoma <ce:cross-refs refid="bb0020 bb0025 bb0030 bb0035" id="cf0095">[4–7]</ce:cross-refs> and dramatic cures in chronic lymphoblastic leukemia <ce:cross-ref refid="bb0015" id="cf0100">[3]</ce:cross-ref>.</ce:para><ce:para id="p0010" view="all">Despite these promising early clinical findings, efforts to increase the fraction of patients showing complete responses (complete and durable elimination of all detectable tumors) are needed. To this end, a variety of strategies are being explored, including manipulation of lymphocyte differentiation state during <ce:italic>ex vivo</ce:italic> expansion <ce:cross-refs refid="bb0040 bb0045 bb0050" id="cf0105">[8–10]</ce:cross-refs>, combination treatments where patients receive adjuvant drug therapies designed to support ACT T-cells <ce:cross-refs refid="bb0020 bb0040 bb0055" id="cf0110">[4,8,11]</ce:cross-refs>, and genetic modification of T-cells to express supporting costimulatory or cytokine genes <ce:cross-refs refid="bb0060 bb0065 bb0070" id="cf0115">[12–14]</ce:cross-refs>. We recently demonstrated that the efficacy of ACT can be dramatically enhanced by conjugation of cytokine- or drug-loaded nanoparticles (NPs) to the surfaces of T-cells <ce:italic>ex vivo</ce:italic> prior to transfer into tumor-bearing recipients <ce:cross-refs refid="bb0075 bb0080" id="cf0120">[15,16]</ce:cross-refs>, creating T-cell “pharmacytes”. T-cell-bound particles provided pseudo-autocrine drug delivery to the transferred cells that greatly increased the effective potency of adjuvant drugs while simultaneously minimizing systemic exposure to these potent supporting signals. This approach allowed autocrine delivery of interleukin cytokines that dramatically enhanced the efficacy of ACT T-cells in a metastatic melanoma model <ce:cross-ref refid="bb0075" id="cf0125">[15]</ce:cross-ref> and the delivery of immunosuppression-blocking drugs that enhanced expansion of T-cells within large established tumors in a prostate cancer model <ce:cross-ref refid="bb0080" id="cf0130">[16]</ce:cross-ref>.</ce:para><ce:para id="p0015" view="all">A limitation of the pharmacyte approach is the one-time nature of the intervention: ACT T-cells can only be loaded once with a cargo of adjuvant drug prior to transfer, and the duration of stimulation is inherently limited by expansion of the cell population <ce:italic>in vivo</ce:italic>, since cell-bound particles are diluted with each cell division. We hypothesized that a strategy to target supporting drugs to T-cells with nanoparticle drug carriers directly <ce:italic>in vivo</ce:italic> would enable transferred lymphocytes to be repeatedly stimulated with supporting adjuvant drugs, and thereby provide continuous supporting signals over the prolonged durations that might be necessary for elimination of large tumor burdens. Such “re-arming” of T-cells with supporting drugs could be achieved by repeated administration of targeted particles, allowing adoptively-transferred T-cells to be restimulated multiple times directly <ce:italic>in vivo</ce:italic>, while the use of internalizing targeting ligands would minimize the likelihood of immune responses against the nanoparticle carrier. To our knowledge, only two prior studies have attempted to target nanoparticles to T-cells <ce:italic>in vivo</ce:italic> <ce:cross-refs refid="bb0085 bb0090" id="cf0135">[17,18]</ce:cross-refs>. In both of these studies, particles were targeted to T-cells <ce:italic>via</ce:italic> peptide-MHC ligands that bind to specific T-cell receptors. However, peptide-MHC-functionalized nanoparticles have recently been shown to deliver an anergizing/tolerizing signal to T-cells <ce:cross-refs refid="bb0090 bb0095" id="cf0140">[18,19]</ce:cross-refs> — which is ideal for treating graft rejection or autoimmunity, but runs counter to the goals of cancer immunotherapy.</ce:para><ce:para id="p0020" view="all">Here we report on initial results illustrating the feasibility of specifically targeting ACT T-cells <ce:italic>in vivo</ce:italic> using stimulatory or non-stimulatory immunoliposomes. We synthesized and characterized PEGylated liposomes conjugated with 2 types of targeting molecules: (1) antibodies against unique cell surface antigens expressed only by the ACT T-cells (here, we employ the congenic marker Thy1.1), mimicking unique surface markers introduced clinically in genetically-engineered ACT T-cells <ce:cross-refs refid="bb0100 bb0105" id="cf0145">[20,21]</ce:cross-refs>; and (2) recombinant interleukin-2 (IL-2), a cytokine that binds the trimeric IL-2 receptor (IL-2R) expressed by activated T lymphocytes <ce:cross-ref refid="bb0110" id="cf0150">[22]</ce:cross-ref>. These two ligands provide contrasting targeting strategies; anti-Thy1.1 provides highly specific targeting without overt stimulation of target cells, while IL-2 provides potentially less specific targeting (IL-2R can be expressed by some endogenous T-cells) but also delivers a direct stimulatory signal to T-cells. We characterized the efficacy of targeting particles to anti-tumor T-cells <ce:italic>in vitro</ce:italic> and internalization of liposomes triggered by these ligands, and then analyzed targeting of ACT T-cells <ce:italic>in vivo</ce:italic> in healthy animals and in a model of metastatic melanoma. Targeted liposomes labeled T-cells in multiple systemic compartments <ce:italic>in vivo</ce:italic>, with anti-Thy1.1 liposomes binding to &gt;<ce:hsp sp="0.10"/>90% of transferred cells following a single injection. Further, we demonstrate the proof of concept that targeted stimulatory IL-2-liposomes can drive repeated expansion of ACT T-cells <ce:italic>in vivo</ce:italic>, following multiple periodic injections of targeted vesicles. We believe this strategy could provide a safe means to amplify the efficacy of ACT while avoiding systemic toxicity associated with many adjuvant drug treatments, and would be translatable to other immunotherapy settings, such as enhancement of cancer vaccines and therapeutic interventions in infectious diseases such as HIV.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:label>2</ce:label><ce:section-title id="st0025">Material and methods</ce:section-title><ce:section id="s0015" view="all"><ce:label>2.1</ce:label><ce:section-title id="st0030">Materials</ce:section-title><ce:para id="p0025" view="all">All lipids and polycarbonate membranes (0.2<ce:hsp sp="0.25"/>μm) for size extrusion were from Avanti Polar Lipids (Alabaster, AL) and used as received. DiD, ACK lysis buffer, Calcium Phosphate Transfection Kit, HEK293 Free Style Cells, Max Efficiency® DH5α™ Competent cells and Phoenix Eco viral packaging cells were obtained from Invitrogen Life Technologies (Grand Island, NY). Anti-thy1.1 (clone 19E12) and mouse IgG<ce:inf loc="post">2a</ce:inf> isotype control antibodies were purchased from BioXCell (West Lebanon, NH). Dithiothreitol (DTT), Fluorescein isothiocyanate (FITC) isomer I, Concanavalin A Type VI (ConA), and Triton X-100 were from Sigma-Aldrich (St. Louis, MO) and used as received. Recombinant IL-2 and IL-7 were purchased from PeproTech (Rocky Hill, NJ). Anti-mouse CD16/32, anti-CD25, anti-CD25-Alexa 488, anti-CD8-PE, anti-Thy1.1, anti-Thy1.1-Percp-Cy5.5 and anti-Thy1.1-FITC were from eBioscience (San Diego, CA). Anti-mouse vβ13 T-cell Receptor-FITC was purchased from Becton Dickinson (Franklin Lakes, NJ). Protein A agarose column and Amicon Ultra-15 30<ce:hsp sp="0.25"/>kDa MWCO Centrifugal Filter Units were from Millipore (Billerica, MA). Polyethylenimine (PEI) was from Polysciences (Warrington, PA). F(ab′)<ce:inf loc="post">2</ce:inf> Preparation Kits, BCA Protein Assay Kits, and Zeba desalting columns were from Pierce Thermo Scientific (Rockford, IL). IL-2 ELISA Kits were obtained from R&amp;D Systems (Minneapolis, MN). Ficoll-Pague Plus was from GE Health Care (Waukesha, WI). EasySep™ Mouse CD8<ce:sup loc="post">+</ce:sup> T Cell Enrichment Kit was from Stemcell (Vancouver, BC, Canada). Collagenase II and Hank's Balanced Salt Solution were purchased from (Gibco-Invitrogen, Carlsbad, CA). EndoFree Plasmid Maxi Kit was from Qiagen (Valencia, CA). Retronectin Recombinant Human Fibronectin Fragment was from Clontech (Mountain View, CA). <ce:small-caps>d</ce:small-caps>-luciferin was from Caliper Life Sciences (Hopkinton, MA). B16F10 melanoma cells were from American Type Culture Collection (Manassas, VA). IL-2-Fc was a generous gift from Dane Wittrup's lab at MIT.</ce:para></ce:section><ce:section id="s0020" view="all"><ce:label>2.2</ce:label><ce:section-title id="st0035">Preparation of IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf></ce:section-title><ce:para id="p0030" view="all">IL-2-Fc is a bivalent fusion protein of the C-terminus of murine wild type IL-2 linked to a mouse IgG<ce:inf loc="post">2a</ce:inf> backbone <ce:cross-ref refid="bb0115" id="cf0155">[23]</ce:cross-ref>. A D265A mutation was introduced in the IgG<ce:inf loc="post">2a</ce:inf> Fc region to minimize interaction of IL-2-Fc with Fc receptors <ce:cross-ref refid="bb0120" id="cf0160">[24]</ce:cross-ref>. IL-2-Fc gene was transformed into DH5α cells <ce:italic>via</ce:italic> heat shock and extracted after clone expansion using an EndoFree Plasmid Maxi Kit following the manufacturer's instructions. HEK293 Freestyle cells were transfected with IL-2-Fc gene/polyethylenimine (PEI) complexes and grown in roller bottles at 37<ce:hsp sp="0.25"/>°C for a week before harvest. Cells were spun down and secreted IL-2-Fc in the supernatant was purified by gravity flow/elution through Protein A agarose columns and concentrated by using centrifugal filter units (Amicon Ultra-15 30<ce:hsp sp="0.25"/>kDa MWCO).</ce:para><ce:para id="p0035" view="all">Monoclonal antibodies (Abs) against Thy1.1 were digested with pepsin to generate the F(ab′)<ce:inf loc="post">2</ce:inf> using a F(ab′)<ce:inf loc="post">2</ce:inf> Preparation Kit following the manufacturer's instructions. IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> concentrations were determined by the BCA Protein Assay Kit. IL-2-Fc bioactivity concentration relative to wild type murine IL-2 was quantified by an IL-2 ELISA Kit.</ce:para></ce:section><ce:section id="s0025" view="all"><ce:label>2.3</ce:label><ce:section-title id="st0040">Synthesis of IL-2-Fc-liposomes and anti-Thy1.1-liposomes</ce:section-title><ce:para id="p0040" view="all">Vacuum dried lipid films composed of 1,2-distearoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000 (maleimide-PEG<ce:inf loc="post">2000</ce:inf>-DSPE)/cholesterol/hydrogenated Soy <ce:small-caps>l</ce:small-caps>-α-phosphatidylcholine (HSPC) in a molar ratio of 2.5/27.5/69 together with 1% of a fluorescent lipophilic tracer dye 1,1′-dioctadecyl-3,3,3′,3′-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate Salt (DiD) were rehydrated in 250<ce:hsp sp="0.25"/>μl of 50<ce:hsp sp="0.25"/>mM HEPES/150<ce:hsp sp="0.25"/>mM NaCl-buffer (pH6.5). Lipids were vortexed every 10<ce:hsp sp="0.25"/>min for 1<ce:hsp sp="0.25"/>h at 62<ce:hsp sp="0.25"/>°C to form vesicles and size extruded through a polycarbonate membrane (0.2<ce:hsp sp="0.25"/>μm). After washing in excess phosphate buffered saline (PBS) pH7.4 and spinning down by ultracentrifugation at 110,000<ce:hsp sp="0.25"/>×<ce:italic>g</ce:italic> for 4<ce:hsp sp="0.25"/>h, liposomes were re-suspended in 100<ce:hsp sp="0.25"/>μl PBS/1.4<ce:hsp sp="0.25"/>mg of lipids.</ce:para><ce:para id="p0045" view="all">IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> were coupled to liposomes as previously described <ce:cross-ref refid="bb0115" id="cf0165">[23]</ce:cross-ref>. Briefly, Ab or cytokine (4–8<ce:hsp sp="0.25"/>mg/ml) was treated with 1.8<ce:hsp sp="0.25"/>mM DTT in the presence of 10<ce:hsp sp="0.25"/>mM EDTA at 25<ce:hsp sp="0.25"/>°C for 20<ce:hsp sp="0.25"/>min to expose hinge region free thiols. DTT was subsequently removed by using Zeba desalting columns before mixing with maleimide-bearing liposomes (1<ce:hsp sp="0.25"/>mg protein/1<ce:hsp sp="0.25"/>mg lipid) in PBS pH 7.4. After incubation for 18<ce:hsp sp="0.25"/>h at 25<ce:hsp sp="0.25"/>°C on a rotator, excess protein was removed by ultracentrifugation in excess PBS (if aggregation occurs, liposomes were size extruded through a 0.2<ce:hsp sp="0.25"/>μm polycarbonate membrane at 37<ce:hsp sp="0.25"/>°C before ultracentrifugation). Liposome sizes were characterized before/after coupling by dynamic light scattering (90Plus Particle Size Analyzer, Brookhaven, Holtsville, NY).</ce:para></ce:section><ce:section id="s0030" view="all"><ce:label>2.4</ce:label><ce:section-title id="st0045">Quantification of targeting ligands coupled to liposomes</ce:section-title><ce:para id="p0050" view="all">Anti-Thy1.1-FITC was concentrated to 4–8<ce:hsp sp="0.25"/>mg/ml using Ultra-15 Centrifugal Filters before coupling to liposomes as previously described. After liposomes were solubilized in 2% Triton X-100 at 37<ce:hsp sp="0.25"/>°C for 5<ce:hsp sp="0.25"/>min with gentle vortexing, FITC fluorescence was measured at ex/em wavelengths of 490/520<ce:hsp sp="0.25"/>nm using a fluorescence plate reader (Tecan Systems, San Jose, CA) and converted to protein concentrations using standard curves prepared from serial dilutions of neat anti-Thy1.1-FITC stock solutions. IL-2-Fc-Lips were solubilized in the same manner and the amount of IL-2 coupled was determined using an IL-2 ELISA Kit (R&amp;D Systems, Minneapolis, MN) following the manufacturer's instructions.</ce:para></ce:section><ce:section id="s0035" view="all"><ce:label>2.5</ce:label><ce:section-title id="st0050">Activation of pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup>CD8<ce:sup loc="post">+</ce:sup> T-cells</ce:section-title><ce:para id="p0055" view="all">Animals were cared for in the USDA-inspected MIT Animal Facility under federal, state, local and NIH guidelines for animal care. Spleens from pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup> mice were ground through a 70<ce:hsp sp="0.25"/>μm cell strainer and red blood cells were removed by incubating with ACK lysis buffer (2<ce:hsp sp="0.25"/>ml/spleen) for 5<ce:hsp sp="0.25"/>min at 25<ce:hsp sp="0.25"/>°C. After 1 wash in PBS, the remaining cells were cultured at 37<ce:hsp sp="0.25"/>°C in RPMI 1640 medium containing 10% fetal calf serum (FCS). ConA at a final concentration of 2<ce:hsp sp="0.25"/>μg/ml and IL-7 at 1<ce:hsp sp="0.25"/>ng/ml were added to activate and expand splenocytes. After two days, dead cells were removed by Ficoll-Pague Plus gradient separation and CD8<ce:sup loc="post">+</ce:sup> T-cells were isolated <ce:italic>via</ce:italic> magnetic negative selection using an EasySep™ Mouse CD8<ce:sup loc="post">+</ce:sup> T Cell Enrichment Kit. Purified CD8<ce:sup loc="post">+</ce:sup> T-cells were re-suspended at 1.5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup>/ml RPMI containing 10<ce:hsp sp="0.25"/>ng/ml recombinant murine IL-2. After 24<ce:hsp sp="0.25"/>h, cells were washed 3 times in PBS and re-suspended in 100<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup>/ml for adoptive transfer.</ce:para><ce:para id="p0060" view="all">For bioluminescence imaging experiments, Click Beetle Red luciferase (CBR-luc) <ce:cross-ref refid="bb0080" id="cf0170">[16]</ce:cross-ref> was introduced into pmel-1 T-cells (post Ficoll purification and magnetic selection) by retroviral transduction. Phoenix Eco viral packaging cells were seeded at 4<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup><ce:hsp sp="0.25"/>cells/10<ce:hsp sp="0.25"/>cm tissue culture dish in 10<ce:hsp sp="0.25"/>ml DMEM medium containing 10% FCS. After incubation overnight at 37<ce:hsp sp="0.25"/>°C, phoenix cells were exchanged with 10<ce:hsp sp="0.25"/>ml fresh DMEM with 10% FCS, transfected with CBR-luc plasmid and Phoenix Eco plasmid using a Calcium Phosphate Transfection Kit and cultured at 32<ce:hsp sp="0.25"/>°C for 24<ce:hsp sp="0.25"/>h. DMEM was then replaced with 6<ce:hsp sp="0.25"/>ml RPMI containing 10% FCS and transfected Phoenix Eco cells were incubated for another 24<ce:hsp sp="0.25"/>h. Supernatant containing the retrovirus-packaged CBR-luc gene was collected and replaced with fresh RPMI for another 24<ce:hsp sp="0.25"/>h incubation. Supernatant was collected again and combined with that collected 24<ce:hsp sp="0.25"/>h earlier, and sterile filtered (0.45<ce:hsp sp="0.25"/>μm). Six-well non-tissue culture plates (BD Falcon) were coated with 1<ce:hsp sp="0.25"/>ml RetroNectin (15<ce:hsp sp="0.25"/>μg/ml) 18<ce:hsp sp="0.25"/>h at 4<ce:hsp sp="0.25"/>°C, then excess RetroNectin was aspirated. Pmel-1 T-cells post ficoll purification and magnetic selection were suspended in filtered viral sups (RPMI collected previously) with 10<ce:hsp sp="0.25"/>ng/ml IL-2 at 1.8<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup>/ml, 3<ce:hsp sp="0.25"/>ml was added to each RetroNection-coated well, and spinoculation was conducted by centrifuging at 2000<ce:hsp sp="0.25"/>×<ce:italic>g</ce:italic> for 1<ce:hsp sp="0.25"/>h at 25<ce:hsp sp="0.25"/>°C. Transduced T-cells were then incubated at 37<ce:hsp sp="0.25"/>°C. Six hours later, 1<ce:hsp sp="0.25"/>ml of fresh RPMI was added with 10<ce:hsp sp="0.25"/>ng/ml IL-2. Transduced, activated pmel-1 T-cells were used 1<ce:hsp sp="0.25"/>day later for adoptive transfer studies.</ce:para></ce:section><ce:section id="s0040" view="all"><ce:label>2.6</ce:label><ce:section-title id="st0055"><ce:italic>In vitro</ce:italic> liposome binding to T-cells</ce:section-title><ce:para id="p0065" view="all">DiD-labeled protein-conjugated liposomes (0.7<ce:hsp sp="0.25"/>mg lipids in 100<ce:hsp sp="0.25"/>μl) were incubated with 15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup> T-cells in 1<ce:hsp sp="0.25"/>ml complete RPMI supplemented with 10% FCS for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C with gentle agitation every 10<ce:hsp sp="0.25"/>min. In competitive conjugation assays, 100-fold molar excess soluble IL-2-Fc or anti-Thy1.1 free antibody (compared to the amount coupled to liposomes) was added 30<ce:hsp sp="0.25"/>min before targeting liposomes to saturate IL-2 or Thy1.1 receptors on the cells, respectively. For IL-2-Fc-Liposome (IL-2-Fc-Lip) competition assays, 2.5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells were mixed with 2.5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> naïve C57Bl/6 splenocytes in 100<ce:hsp sp="0.25"/>μl complete RPMI with 10% FCS. The cell mixture was incubated with or without 0.24<ce:hsp sp="0.25"/>mg/ml soluble IL-2-Fc, followed by incubation with 0.07<ce:hsp sp="0.25"/>mg/ml IL-2-Fc-Lip for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C with total volume topped up to 300<ce:hsp sp="0.25"/>μl. For competition assays with anti-thy1.1.-liposome (anti-Thy1.1-Lip), 0.15<ce:hsp sp="0.25"/>mg/ml liposomes (Lip) were incubated with a mixture of 2.5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 T-cells and 2.5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> naïve C57Bl/6 splenocytes (with or without pre-blocking by 1.34<ce:hsp sp="0.25"/>mg/ml anti-Thy1.1). Cells without any liposomes added served as a control for cellular autofluorescence and cells conjugated with 0.15<ce:hsp sp="0.25"/>mg/ml IgG<ce:inf loc="post">2a</ce:inf>-liposomes (IgG<ce:inf loc="post">2a</ce:inf>-Lip) were used to test non-specific binding of non-targeting liposomes. For all <ce:italic>in vitro</ce:italic> conjugation experiments, cells were stained with anti-CD8 and anti-Thy1.1 after two washes in ice cold PBS to remove unbound liposomes, and analyzed by flow cytometry on a BD FACS Canto except competition assays which were done on a BD LSR II.</ce:para></ce:section><ce:section id="s0045" view="all"><ce:label>2.7</ce:label><ce:section-title id="st0060">Titration of liposome concentration for <ce:italic>in vitro</ce:italic> conjugation</ce:section-title><ce:para id="p0070" view="all">Varying amounts of DiD-labeled anti-Thy1.1-Lip were added to 5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup> T-cells in 100<ce:hsp sp="0.25"/>μl complete RPMI with 10% FCS. The total volume for all groups was topped up with RPMI with 10% FCS to 300<ce:hsp sp="0.25"/>μl and incubated at 37<ce:hsp sp="0.25"/>°C for 30<ce:hsp sp="0.25"/>min. After two washes in ice cold PBS to remove unbound liposomes, cells were resuspended in FACS buffer, surface stained with fluorescently labeled anti-CD8 and anti-Thy1.1, and analyzed by flow cytometry on a BD LSR II.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:label>2.8</ce:label><ce:section-title id="st0065">Internalization of liposomes</ce:section-title><ce:para id="p0075" view="all">Anti-Thy1.1-Liposomes were labeled with 1% (mol) carboxyfluorescein-1,2-dioleoyl-<ce:italic>sn</ce:italic>-glycero-3-phosphoethanolamine lipid (CF-DOPE) instead of DiD during the synthesis stage and incubated with 6<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup><ce:hsp sp="0.25"/>activated pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup> T-cells/0.7<ce:hsp sp="0.25"/>mg of lipids for 60<ce:hsp sp="0.25"/>min at 4<ce:hsp sp="0.25"/>°C with gentle agitation every 15<ce:hsp sp="0.25"/>min. After two washes in ice cold PBS pH7.4 to remove unbound liposomes, T-cells were resuspended in RPMI and aliquotted into four equal portions for 0, 2, 4 and 6<ce:hsp sp="0.25"/>h time points, respectively. After each incubation interval at 37<ce:hsp sp="0.25"/>°C, T-cells were washed 2<ce:hsp sp="0.10"/>× in ice cold PBS and re-suspended in flow cytometry buffer (2% FCS in PBS). Cells were placed on ice to minimize further internalization and analyzed by flow cytometry on a BD LSR II. Cells were also imaged directly without fixation on a Zeiss LSM 510 laser scanning confocal microscope.</ce:para></ce:section><ce:section id="s0055" view="all"><ce:label>2.9</ce:label><ce:section-title id="st0070">Adoptive transfer and <ce:italic>in vivo</ce:italic> liposome targeting</ce:section-title><ce:para id="p0080" view="all">Albino C57BL/6 female mice 6–8<ce:hsp sp="0.25"/>weeks of age were from the Jackson Laboratory (Bar Harbor, ME). One day before adoptive transfer, mice were sublethally lymphodepleted with 5<ce:hsp sp="0.25"/>Gy total body irradiation. 15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells in 150<ce:hsp sp="0.25"/>μl PBS were injected intravenously (i.v.) into each recipient animal. DiD-labeled immunoliposomes (1.4<ce:hsp sp="0.25"/>mg lipids) were re-suspended in 100<ce:hsp sp="0.25"/>μl PBS and injected i.v. immediately or three days after adoptive transfer. Twenty-four hours after administration of liposomes, mice were euthanized and blood, lymph node, and spleen cells were analyzed by flow cytometry on a BD FACS Canto to assess liposome binding to T-cells.</ce:para></ce:section><ce:section id="s0060" view="all"><ce:label>2.10</ce:label><ce:section-title id="st0075">Adoptive transfer of CBR-Luc T-cells and bioluminescence imaging</ce:section-title><ce:para id="p0085" view="all">B16F10 melanoma cells were suspended at 1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup><ce:hsp sp="0.25"/>cells/200<ce:hsp sp="0.25"/>μl in Hank's Balanced Salt Solution and injected i.v. to induce lung metastases in albino C57Bl/6 mice (day −<ce:hsp sp="0.10"/>8). Animals were then sublethally lymphodepleted by total body irradiation (5<ce:hsp sp="0.25"/>Gy) 7<ce:hsp sp="0.25"/>days post tumor inoculation (day −<ce:hsp sp="0.10"/>1). Pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells transduced with CBR-Luc (12<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup>) were resuspended in 150<ce:hsp sp="0.25"/>μl PBS and administered i.v. one day after lymphodepletion (day 0). IL-2-Fc-Lip (1<ce:hsp sp="0.25"/>mg of liposomes) or PBS was injected i.v. immediately after ACT and on day 6. <ce:small-caps>d</ce:small-caps>-Luciferin, a substrate for CBR-luc, was suspended in PBS (15<ce:hsp sp="0.25"/>mg/ml) and 150<ce:hsp sp="0.25"/>mg luciferin/kg body weight was injected Intraperitoneally (i.p.) in anesthetized animals 10<ce:hsp sp="0.25"/>min before bioluminescence imaging acquisitions (5<ce:hsp sp="0.25"/>min, 3<ce:hsp sp="0.25"/>min, 2<ce:hsp sp="0.25"/>min and 1<ce:hsp sp="0.25"/>min) on a Xenogen IVIS Spectrum Imaging System (Caliper Life Sciences). Images were collected every two days starting from day 0 (2<ce:hsp sp="0.25"/>h after ACT) to day 14. Living Image software version 3.0 (Caliper Life Sciences) was used to acquire and quantitate the bioluminescence imaging data sets. To compare the stimulatory effects of soluble IL-2 and IL-2-Fc-Lip, a similar experiment was repeated with 1st/2nd dose as 0.5<ce:hsp sp="0.25"/>mg/1<ce:hsp sp="0.25"/>mg IL-2-Fc-Lip or 10<ce:hsp sp="0.25"/>μg/20<ce:hsp sp="0.25"/>μg soluble recombinant wild type mouse IL-2 (PeproTech, Rocky Hill, NJ), equivalent to the amount of IL-2 coupled on IL-2-Fc-Lip). On day 12 mice were sacrificed and T-cells from inguinal lymph nodes were collected and surface stained for CD8 and vβ13 before analyzing by flow cytometry on a BD FACS Canto to assess the percentage of tumor-specific T-cells in each group.</ce:para></ce:section><ce:section id="s0065" view="all"><ce:label>2.11</ce:label><ce:section-title id="st0080">Sample preparation for flow cytometry</ce:section-title><ce:para id="p0090" view="all">Inguinal lymph nodes and spleens were ground through a 70<ce:hsp sp="0.25"/>μm cell strainer and washed once with ice cold PBS. Splenocytes were then lysed with ACK lysis buffer (2<ce:hsp sp="0.25"/>ml/spleen) for 5<ce:hsp sp="0.25"/>min at 25<ce:hsp sp="0.25"/>°C to remove red blood cells before washing in ice cold PBS. Blood samples were lysed 2<ce:hsp sp="0.10"/>× with 1<ce:hsp sp="0.25"/>ml ACK lysis buffer for 5<ce:hsp sp="0.25"/>min at 25<ce:hsp sp="0.25"/>°C and then washed 1<ce:hsp sp="0.10"/>× with ice cold PBS. All cells were washed in FACS buffer (PBS with 2% Fetal Calf Serum) once before surface-staining with Ab. After staining, cells were washed 2<ce:hsp sp="0.10"/>× in FACS buffer and analyzed on a BD FACS Canto Flow Cytometer. All data were processed using FlowJo software.</ce:para></ce:section><ce:section id="s0070" view="all"><ce:label>2.12</ce:label><ce:section-title id="st0085">Statistical analysis</ce:section-title><ce:para id="p0095" view="all">Statistical analysis was done using GraphPad Prism software and two-tailed unpaired t-tests were conducted between groups of experimental data. Graphs show the mean<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>SEM of sample groups.</ce:para></ce:section></ce:section><ce:section id="s0075" view="all"><ce:label>3</ce:label><ce:section-title id="st0090">Results and discussion</ce:section-title><ce:section id="s0080" view="all"><ce:label>3.1</ce:label><ce:section-title id="st0095">Synthesis and characterization of IL-2-Fc-Lip and anti-Thy1.1-Lip</ce:section-title><ce:para id="p0100" view="all">To generate cytokine- or antibody (Ab)-conjugated liposomes (IL-2-Fc-Lip or anti-Thy1.1-Lip) for T-cell targeting, PEGylated liposomes incorporating maleimide-headgroup PEG-lipids (Mal-PEG-DSPE) were prepared from high-T<ce:inf loc="post">m</ce:inf> lipids and sized by membrane filtration to a mean diameter of 173<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>13<ce:hsp sp="0.25"/>nm (<ce:cross-ref refid="f0010" id="cf0175">Fig. 1</ce:cross-ref>A, B<ce:float-anchor refid="f0010"/>). Murine IL-2 fused to the C-terminus of mouse IgG<ce:inf loc="post">2a</ce:inf> Fc or anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> were coupled to the maleimide termini of PEG chains to serve as targeting ligands of the immunoliposomes. To minimize interaction of liposomes with phagocyte Fc receptors, a D265A mutation was introduced in the Fc portion of IL-2-Fc <ce:cross-ref refid="bb0120" id="cf0180">[24]</ce:cross-ref> and F(ab′)<ce:inf loc="post">2</ce:inf> fragments of anti-Thy1.1 monoclonal antibodies were generated by pepsin digestion. Prior to F(ab′)<ce:inf loc="post">2</ce:inf>/cytokine coupling, IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> were mildly reduced by DTT to expose hinge region free thiols for reaction with the liposome maleimide functional head groups. We tested liposomes containing two different mole fractions of maleimide-PEG lipid (1 or 2.5<ce:hsp sp="0.25"/>mol% of total lipids), and found greater targeting ligand conjugation with higher fractions of maleimide-lipid, as expected (<ce:cross-ref refid="f0010" id="cf0185">Fig. 1</ce:cross-ref>C). Negligible IL-2 or F(ab′)<ce:inf loc="post">2</ce:inf> binding to liposomes was observed in the absence of the maleimide reactive groups. Liposomes with 2.5<ce:hsp sp="0.25"/>mol% mal-PEG-DSPE gave 23<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>2<ce:hsp sp="0.25"/>μg of IL-2 (cytokine equivalent, or 1.4<ce:hsp sp="0.25"/>nmol IL-2) or 76<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>7<ce:hsp sp="0.25"/>μg of anti-Thy1.1 (0.5<ce:hsp sp="0.25"/>nmol<ce:hsp sp="0.25"/>F(ab′)<ce:inf loc="post">2</ce:inf>)/mg lipid after overnight coupling at 25<ce:hsp sp="0.25"/>°C. As shown in <ce:cross-ref refid="f0010" id="cf0190">Fig. 1</ce:cross-ref>B, targeting ligand conjugation caused a slight increase in the mean size of the vesicles from 173<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>13<ce:hsp sp="0.25"/>nm to 186<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>16<ce:hsp sp="0.25"/>nm.</ce:para></ce:section><ce:section id="s0085" view="all"><ce:label>3.2</ce:label><ce:section-title id="st0100">IL-2-Fc-Lip and anti-Thy1.1-Lip binding to T-cells <ce:italic>in vitro</ce:italic></ce:section-title><ce:para id="p0105" view="all">To generate a target population of T-cells to be used in adoptive transfer studies, CD8<ce:sup loc="post">+</ce:sup> T-cells from pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup> mice (which express a transgenic T-cell receptor specific for the gp100 antigen of melanoma <ce:cross-ref refid="bb0125" id="cf0195">[25]</ce:cross-ref>) were isolated by magnetic negative selection from activated splenocytes, and expanded by culturing with IL-2 for 1<ce:hsp sp="0.25"/>day to obtain an elevated expression of CD25 (the α-chain of the trimeric IL-2 receptor) compared to naive pmel-1 or naive polyclonal C57Bl/6 CD8<ce:sup loc="post">+</ce:sup> T-cells (<ce:cross-ref refid="f0015" id="cf0200">Fig. 2</ce:cross-ref>A<ce:float-anchor refid="f0015"/> and data not shown). Fluorescently labeled PEGylated vesicles showed very low background binding to activated pmel-1 T-cells following a 30<ce:hsp sp="0.25"/>min incubation at 37° <ce:italic>in vitro</ce:italic>, but IL-2-Fc-Lip or anti-Thy1.1-Lip containing 1% or 2.5% maleimide functional groups efficiently bound to activated pmel-1 T-cells (<ce:cross-ref refid="f0015" id="cf0205">Fig. 2</ce:cross-ref>B). The Mean Fluorescence Intensities (MFI) of cells after conjugation with different types of liposomes was quantified; the high expression levels of Thy1.1 on pmel-1 T-cells led to much greater per-cell binding of anti-Thy1.1-Lip <ce:italic>vs.</ce:italic> IL-2-Fc-Lip (<ce:cross-ref refid="f0015" id="cf0210">Fig. 2</ce:cross-ref>C). For both targeting ligands, liposomes containing 2.5<ce:hsp sp="0.25"/>mol% mal-PEG-DSPE (and therefore with higher ligand densities) achieved much greater binding to T-cells than vesicles with 1<ce:hsp sp="0.25"/>mol% of the maleimide lipid, with MFIs of bound liposomes increased by 6-fold and 4-fold for anti-Thy1.1-Lip and IL-2-Fc-Lip, respectively (<ce:cross-ref refid="f0015" id="cf0215">Fig. 2</ce:cross-ref>B, C).</ce:para><ce:para id="p0110" view="all">To evaluate the specificity of anti-Thy1.1-Lip and IL-2-Fc-Lip binding, we assessed T-cell labeling in the presence of competing free IL-2-Fc or anti-Thy1.1 Abs added to a 1:1 mixture of naïve C57Bl/6 lymphocytes and pmel-1 T-cells 30<ce:hsp sp="0.25"/>min before the targeted vesicles. IL-2-Fc-Lip bound to activated pmel-1 T-cells, but not naïve C57Bl/6 CD8<ce:sup loc="post">+</ce:sup> T cells that lack IL-2 receptors (<ce:cross-ref refid="f0015" id="cf0220">Fig. 2</ce:cross-ref>D middle left). Pre-blocking pmel-1 T-cells with soluble IL-2-Fc blocked 90% of binding to pmel-1 T-cells (<ce:cross-ref refid="f0015" id="cf0225">Fig. 2</ce:cross-ref>D middle right, E). Similarly, anti-Thy1.1-Lip selectively targeted pmel-1 CD8<ce:sup loc="post">+</ce:sup> T cells but not naive C57Bl/6 (Thy1.2<ce:sup loc="post">+</ce:sup>) CD8<ce:sup loc="post">+</ce:sup> T cells (<ce:cross-ref refid="f0015" id="cf0230">Fig. 2</ce:cross-ref>D bottom left). Pre-incubation of pmel-1 T-cells with anti-Thy1.1 lowered anti-Thy1.1-Lip binding by 99% (<ce:cross-ref refid="f0015" id="cf0235">Fig. 2</ce:cross-ref>D bottom right, E). Autofluorescence and non-specific binding of non-targeted control IgG<ce:inf loc="post">2a</ce:inf>-Lip were negligible (<ce:cross-ref refid="f0015" id="cf0240">Fig. 2</ce:cross-ref>D top left and right, E). As expected from the pM affinity of IL-2 for its receptor <ce:cross-refs refid="bb0130 bb0135" id="cf0245">[26,27]</ce:cross-refs> and the typical nM affinity of commercial antibodies, liposomes at concentration of 0.4<ce:hsp sp="0.25"/>mg/ml (equivalent to 2<ce:hsp sp="0.25"/>nM of liposomes) labeled 100% of activated pmel-1 T-cells <ce:italic>in vitro</ce:italic>, and liposome binding reached a plateau at concentrations higher than 0.4<ce:hsp sp="0.25"/>mg/ml (equivalent to 2<ce:hsp sp="0.25"/>nM liposomes) (<ce:cross-ref refid="f0015" id="cf0250">Fig. 2</ce:cross-ref>F). Thus, both IL-2- and anti-Thy1.1-targeted stealth liposomes achieve specific and avid binding to primed pmel-1 CD8<ce:sup loc="post">+</ce:sup> T-cells. Even when the concentration was titrated down to 0.1<ce:hsp sp="0.25"/>mg/ml, nearly 100% of cells were still labeled with liposomes, albeit with fewer liposomes bound per cell.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:label>3.3</ce:label><ce:section-title id="st0105">Internalization of Anti-Thy1.1-conjugated liposomes</ce:section-title><ce:para id="p0115" view="all">We previously reported that IL-2-Fc-conjugated liposomes are rapidly internalized by activated T-cells <ce:italic>in vitro</ce:italic> <ce:cross-ref refid="bb0140" id="cf0255">[28]</ce:cross-ref>. To determine whether anti-Thy1.1-Lip would also trigger liposome endocytosis, we added anti-Thy1.1-Lip incorporating a carboxyfluorescein (CF)-headgroup lipid to pmel-1 T-cells at 4<ce:hsp sp="0.25"/>°C to allow binding without internalization, then warmed the cells to 37<ce:hsp sp="0.25"/>°C and assessed cell-associated fluorescence over time. Fluorescein has highly pH-sensitive fluorescence that is strongly quenched at acidic pHs <ce:cross-ref refid="bb0145" id="cf0260">[29]</ce:cross-ref>. The high avidity of liposome binding to cells led to no measurable release of free liposomes into the supernatant over 6<ce:hsp sp="0.25"/>h at 37<ce:hsp sp="0.25"/>°C (not shown); we thus attributed loss of the CF tracer signal to endocytic uptake by labeled cells. Over a time course of 6<ce:hsp sp="0.25"/>h, the MFI of liposome-labeled T-cells steadily dropped, corresponding to roughly 90% internalization over this time course (<ce:cross-ref refid="f0020" id="cf0265">Fig. 3</ce:cross-ref>A<ce:float-anchor refid="f0020"/>). Confocal imaging also showed that anti-Thy1.1-Lip fluorescence initially localized to the plasma membrane of labeled cells was largely lost by 6<ce:hsp sp="0.25"/>h (<ce:cross-ref refid="f0020" id="cf0270">Fig. 3</ce:cross-ref>B).</ce:para></ce:section><ce:section id="s0095" view="all"><ce:label>3.4</ce:label><ce:section-title id="st0110"><ce:italic>In vivo</ce:italic> targeting of IL-2-Fc-Lip and anti-Thy1.1-Lip in healthy animals</ce:section-title><ce:para id="p0120" view="all">Next, we tested the capacity of anti-Thy1.1-Lip and IL-2-Fc-Lip to target pmel-1 T-cells <ce:italic>in vivo</ce:italic> in healthy mice. PEGylated liposomes conjugated with isotype control murine IgG<ce:inf loc="post">2a</ce:inf> were prepared to serve as a control non-T-cell-targeting liposome. To model clinical adoptive T-cell therapy, recipient Thy1.2<ce:sup loc="post">+</ce:sup> C57Bl/6 mice were lymphodepleted by sublethal irradiation, followed by i.v. injection of 15<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> activated pmel-1 Thy1.1<ce:sup loc="post">+</ce:sup>CD8<ce:sup loc="post">+</ce:sup> T-cells one day later. Lymphodepletion removes cytokine sinks and regulatory T-cells to allow more efficient expansion and effector function of transferred T-cells <ce:cross-refs refid="bb0150 bb0155" id="cf0275">[30,31]</ce:cross-refs>. To assess T-cell targeting, IgG<ce:inf loc="post">2a</ce:inf>-Lip, IL-2-Fc-Lip, or anti-Thy1.1-Lip fluorescently labeled with the non-pH-sensitive tracer DiD were injected i.v. either immediately after adoptive transfer or 3<ce:hsp sp="0.25"/>days after T-cell injection. Twenty-four hours after liposome injection, cells from the blood, lymph nodes (LNs), and spleens were analyzed by flow cytometry to assess binding of fluorescent liposomes (<ce:cross-ref refid="f0025" id="cf0280">Fig. 4</ce:cross-ref>A<ce:float-anchor refid="f0025"/>). Thy1.1 expression allowed liposome binding to transferred pmel-1 T-cells to be distinguished from endogenous T-cells (<ce:cross-ref refid="f0025" id="cf0285">Fig. 4</ce:cross-ref>B). Sample flow cytometry histograms are shown in <ce:cross-ref refid="f0025" id="cf0290">Fig. 4</ce:cross-ref>C, illustrating conjugation efficiencies of IgG<ce:inf loc="post">2a</ce:inf>-Lip, IL-2-Fc-Lip, and anti-Thy1.1-Lip obtained when liposomes were injected immediately after ACT T-cells. The percentage endogenous or ACT CD8<ce:sup loc="post">+</ce:sup> T-cells labeled by each type of liposome in the blood (<ce:cross-ref refid="f0025" id="cf0295">Fig. 4</ce:cross-ref>D), lymph nodes (<ce:cross-ref refid="f0025" id="cf0300">Fig. 4</ce:cross-ref>E) and spleens (<ce:cross-ref refid="f0025" id="cf0305">Fig. 4</ce:cross-ref>F) were assessed; this analysis revealed that IgG<ce:inf loc="post">2a</ce:inf>-Lip exhibited low binding to both T-cell populations. In contrast, anti-Thy1.1-Lip labeled nearly 100% of the transferred T-cells in the blood and spleen whether injected on day 0 or day 3. The slightly greater background binding of isotype control IgG2a-Lip to ACT <ce:italic>vs.</ce:italic> endogenous T-cells in spleens was found to be an artifact of the liposome dose; injection of lower liposome doses of 0.18<ce:hsp sp="0.25"/>mg (approximately ~<ce:hsp sp="0.10"/>0.1<ce:hsp sp="0.25"/>mg/ml liposomes in the blood) led to a similar efficiency of specific T-cell binding but eliminated the low differential background binding to ACT <ce:italic>vs.</ce:italic> endogenous T-cells (data not shown). A lower fraction of T-cells in lymph nodes were labeled by anti-Thy1.1-Lip following a day 3 injection, which may reflect a combination of poor entry of targeted liposomes into LN and/or incomplete recirculation of T-cells from LN back into the blood in the 24<ce:hsp sp="0.25"/>h time window between liposome injection and our analysis. Anti-Thy1.1-Lip also showed low levels of background binding to endogenous (Thy1.1<ce:sup loc="post">−</ce:sup>) T-cells. IL-2-Fc-Lip labeled the majority of pmel-1 T-cells in the LNs, spleen and blood when injected just after T-cells, and also showed relatively low binding to endogenous T-cells. However, injection of IL-2Fc-Lip on day 3 led to relatively poor T-cell labeling in the blood and LNs, while still labeling a majority of ACT T-cells in the spleen. Poor labeling by IL-2-Fc-Lip on day 3 reflected rapid downregulation of the IL-2R <ce:italic>in vivo</ce:italic> following T-cell transfer in the absence of antigen (data not shown). Thus, both IL-2-Fc and anti-Thy1.1 F(ab′)<ce:inf loc="post">2</ce:inf> can be effective for specifically targeting adoptively transferred T-cells <ce:italic>in vivo</ce:italic>, though modulation of IL-2R levels by T-cells over time is an important consideration for achieving effective targeting.</ce:para></ce:section><ce:section id="s0100" view="all"><ce:label>3.5</ce:label><ce:section-title id="st0115">IL-2-Fc-Lip permit repeated boosting of ACT T-cells in a murine lung metastasis model</ce:section-title><ce:para id="p0125" view="all">To test the potential functional impact of stimulatory T-cell targeted liposomes, we assessed the response of pmel-1 melanoma-specific T-cells <ce:italic>in vivo</ce:italic> during ACT treatment of B16F10 tumors in a metastatic lung tumor model. B16F10 melanoma cells were injected <ce:italic>via</ce:italic> the tail vein to allow lung metastases to establish for 10<ce:hsp sp="0.25"/>days, then animals were lymphodepleted and received adoptive transfer of luciferase-expressing pmel-1 melanoma-specific CD8<ce:sup loc="post">+</ce:sup> T-cells (<ce:cross-ref refid="f0030" id="cf0310">Fig. 5</ce:cross-ref>A<ce:float-anchor refid="f0030"/>). In one group of animals, T-cell expansion was followed over time by bioluminescence imaging without further treatment, while in other two groups of mice, the adoptively-transferred cells were boosted on days 0 and 6 by injection of IL-2-Fc-Lip. Adoptively transferred cells without further adjuvant support showed a low level persistence in the tumor-bearing recipients that gradually declined over 14<ce:hsp sp="0.25"/>days, as expected in the absence of additional stimulation or protection from tumor immunosuppression <ce:cross-ref refid="bb0125" id="cf0315">[25]</ce:cross-ref> (<ce:cross-ref refid="f0030" id="cf0320">Fig. 5</ce:cross-ref>B, C). In contrast, following injection of the first dose of IL-2-Fc-Lip, pmel-1 T-cells expanded 3-fold more than the control T-cell therapy group. These boosted T-cells began to contract again between day 4 and day 6, but following a second dose of IL-2-Fc-Lip, re-expanded to an even greater level, reaching a peak by day 10 with 6-fold greater T-cell numbers relative to the T-cell-only treatment group (<ce:cross-ref refid="f0030" id="cf0325">Fig. 5</ce:cross-ref>B, C). To assess the relative potency of stimulation achieved by IL-2-Fc-Lip compared to traditional systemic IL-2 therapy, we repeated this ACT experiment and compared the expansion of T-cells following injection of IL-2-Fc-Lip or soluble IL-2 (at an equivalent total amount of cytokine to that bound to the liposomes) on day 0 and day 6. Flow cytometry analysis of T-cells pooled from the inguinal lymph nodes 12<ce:hsp sp="0.25"/>days after adoptive transfer confirmed that the frequency of tumor-specific CD8<ce:sup loc="post">+</ce:sup> T-cells (pmel-1 T-cells express the Vβ13 TCR β chain) was nearly 3 times greater in animals that received IL-2-Fc-Lip injections compared to T-cells alone (<ce:cross-ref refid="f0030" id="cf0330">Fig. 5</ce:cross-ref>D–E). Further, soluble IL-2 at these doses showed no enhancement in T-cell expansion. The difference between the potency of IL-2-Fc-Lip and soluble IL-2 may reflect the very short half-life of IL-2 <ce:italic>in vivo</ce:italic> <ce:cross-ref refid="bb0160" id="cf0335">[32]</ce:cross-ref>, which the PEGylated liposomes may partly overcome. Notably, this enhanced potency was not accompanied by overt toxicity as assessed by changes in animal weights during the therapy (data not shown). Thus, IL-2-targeted liposomes allow multiple boosts of ACT T-cells <ce:italic>in vivo</ce:italic>, leading to repeated waves of T-cells expansion in tumor-bearing animals, which exceed the response elicited by systemic free IL-2.</ce:para></ce:section></ce:section><ce:section id="s0105" view="all"><ce:label>4</ce:label><ce:section-title id="st0120">Conclusions</ce:section-title><ce:para id="p0130" view="all">Here we synthesized and characterized antibody- and cytokine-decorated immunoliposomes targeting unique cell surface antigens or activation markers on T-cells, respectively. Targeting liposomes bound to ACT T-cells specifically <ce:italic>in vitro</ce:italic>, and further, anti-Thy1.1-Lip also labeled nearly 100% of transferred T-cells in systemic compartments and most of transferred T-cells in LN <ce:italic>in vivo</ce:italic> following a single injection of targeted vesicles. Despite its lower targeting specificity compared to anti-Thy1.1-Lip, IL-2-Fc-Lip was able to repeatedly boost transferred T-cells <ce:italic>in vivo</ce:italic> in tumor-bearing animals and provide direct stimulation to ACT T-cells. We focused here on an initial characterization of <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> T-cell targeting, and future work will examine the therapeutic efficacy of ACT cell targeting with drug-loaded liposomes. However, these results demonstrate the concept of repeated targeting of ACT T-cells for adjuvant stimulation <ce:italic>in vivo</ce:italic>. This data sets the stage for functional targeting of supporting adjuvant drugs or imaging contrast agents to T-cells, in order to enhance the efficacy of ACT and/or permit longitudinal tracking of ACT T-cells <ce:italic>in vivo</ce:italic>.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0125">Acknowledgments</ce:section-title><ce:para id="p0135" view="all">We thank Prof. K. Dane Wittrup for the gift of engineered IL-2-Fc. This work was supported in part by the <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">NIH</ce:grant-sponsor> (<ce:grant-number refid="gts0005">CA140476</ce:grant-number> and <ce:grant-number refid="gts0005">CA172164</ce:grant-number>), the <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Dept. of Defense</ce:grant-sponsor> (contract <ce:grant-number refid="gts0010">W81XWH-10-1-0290</ce:grant-number>), and by the <ce:grant-sponsor id="gts0015" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Koch Institute Support</ce:grant-sponsor> (core) Grant <ce:grant-number refid="gts0020">P30-CA14051</ce:grant-number> from the <ce:grant-sponsor id="gts0020" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Cancer Institute</ce:grant-sponsor>. DJI is an investigator of the Howard Hughes Medical Institute. The authors wish to dedicate this paper to the memory of Officer Sean Collier, for his caring service and sacrifice in protecting the MIT community.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0130">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>[1]</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Mellman</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Coukos</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Dranoff</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cancer immunotherapy comes of age</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>480</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>480</sb:first-page><sb:last-page>489</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>[2]</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Topalian</ce:surname></sb:author><sb:author><ce:given-name>F.S.</ce:given-name><ce:surname>Hodi</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Brahmer</ce:surname></sb:author><sb:author><ce:given-name>S.N.</ce:given-name><ce:surname>Gettinger</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Smith</ce:surname></sb:author><sb:author><ce:given-name>D.F.</ce:given-name><ce:surname>McDermott</ce:surname></sb:author><sb:author><ce:given-name>J.D.</ce:given-name><ce:surname>Powderly</ce:surname></sb:author><sb:author><ce:given-name>R.D.</ce:given-name><ce:surname>Carvajal</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Sosman</ce:surname></sb:author><sb:author><ce:given-name>M.B.</ce:given-name><ce:surname>Atkins</ce:surname></sb:author><sb:author><ce:given-name>P.D.</ce:given-name><ce:surname>Leming</ce:surname></sb:author><sb:author><ce:given-name>D.R.</ce:given-name><ce:surname>Spigel</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Antonia</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Horn</ce:surname></sb:author><sb:author><ce:given-name>C.G.</ce:given-name><ce:surname>Drake</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Pardoll</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>W.H.</ce:given-name><ce:surname>Sharfman</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Anders</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Taube</ce:surname></sb:author><sb:author><ce:given-name>T.L.</ce:given-name><ce:surname>McMiller</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Xu</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Korman</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Jure-Kunkel</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Agrawal</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>McDonald</ce:surname></sb:author><sb:author><ce:given-name>G.D.</ce:given-name><ce:surname>Kollia</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Gupta</ce:surname></sb:author><sb:author><ce:given-name>J.M.</ce:given-name><ce:surname>Wigginton</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sznol</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>N. Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>366</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>2443</sb:first-page><sb:last-page>2454</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>[3]</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kalos</ce:surname></sb:author><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Levine</ce:surname></sb:author><sb:author><ce:given-name>D.L.</ce:given-name><ce:surname>Porter</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Katz</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Grupp</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bagg</ce:surname></sb:author><sb:author><ce:given-name>C.H.</ce:given-name><ce:surname>June</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Sci. Transl. Med.</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>95ra73</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>[4]</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Sherry</ce:surname></sb:author><sb:author><ce:given-name>U.S.</ce:given-name><ce:surname>Kammula</ce:surname></sb:author><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Hughes</ce:surname></sb:author><sb:author><ce:given-name>G.Q.</ce:given-name><ce:surname>Phan</ce:surname></sb:author><sb:author><ce:given-name>D.E.</ce:given-name><ce:surname>Citrin</ce:surname></sb:author><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author><sb:author><ce:given-name>P.F.</ce:given-name><ce:surname>Robbins</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Wunderlich</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Morton</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Laurencot</ce:surname></sb:author><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Steinberg</ce:surname></sb:author><sb:author><ce:given-name>D.E.</ce:given-name><ce:surname>White</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Dudley</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>17</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>4550</sb:first-page><sb:last-page>4557</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>[5]</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Yee</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Thompson</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Byrd</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Riddell</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Roche</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Celis</ce:surname></sb:author><sb:author><ce:given-name>P.D.</ce:given-name><ce:surname>Greenberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adoptive T cell therapy using antigen-specific CD8<ce:sup loc="post">+</ce:sup> T cell clones for the treatment of patients with metastatic melanoma: <ce:italic>in vivo</ce:italic> persistence, migration, and antitumor effect of transferred T cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>99</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>16168</sb:first-page><sb:last-page>16173</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>[6]</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Morgan</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Dudley</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Wunderlich</ce:surname></sb:author><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Hughes</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Sherry</ce:surname></sb:author><sb:author><ce:given-name>R.E.</ce:given-name><ce:surname>Royal</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Topalian</ce:surname></sb:author><sb:author><ce:given-name>U.S.</ce:given-name><ce:surname>Kammula</ce:surname></sb:author><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Zheng</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Nahvi</ce:surname></sb:author><sb:author><ce:given-name>C.R.</ce:given-name><ce:surname>de Vries</ce:surname></sb:author><sb:author><ce:given-name>L.J.</ce:given-name><ce:surname>Rogers-Freezer</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Mavroukakis</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cancer regression in patients after transfer of genetically engineered lymphocytes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>314</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>126</sb:first-page><sb:last-page>129</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>[7]</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Dudley</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Adoptive immunotherapy for cancer: harnessing the T cell response</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Rev. Immunol.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>269</sb:first-page><sb:last-page>281</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>[8]</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Besser</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Shapira-Frommer</ce:surname></sb:author><sb:author><ce:given-name>A.J.</ce:given-name><ce:surname>Treves</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Zippel</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Itzhaki</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Hershkovitz</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Levy</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kubi</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Hovav</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Chermoshniuk</ce:surname></sb:author><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Shalmon</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Hardan</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Catane</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Markel</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Apter</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Ben-Nun</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Kuchuk</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shimoni</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Nagler</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Schachter</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>2646</sb:first-page><sb:last-page>2655</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>[9]</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.P.</ce:given-name><ce:surname>Rubinstein</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Cloud</ce:surname></sb:author><sb:author><ce:given-name>T.E.</ce:given-name><ce:surname>Garrett</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Moore</ce:surname></sb:author><sb:author><ce:given-name>K.M.</ce:given-name><ce:surname>Schwartz</ce:surname></sb:author><sb:author><ce:given-name>C.B.</ce:given-name><ce:surname>Johnson</ce:surname></sb:author><sb:author><ce:given-name>D.H.</ce:given-name><ce:surname>Craig</ce:surname></sb:author><sb:author><ce:given-name>M.L.</ce:given-name><ce:surname>Salem</ce:surname></sb:author><sb:author><ce:given-name>C.M.</ce:given-name><ce:surname>Paulos</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Cole</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle><ce:italic>Ex vivo</ce:italic> interleukin-12-priming during CD8<ce:sup loc="post">+</ce:sup> T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Am. Coll. Surg.</sb:maintitle></sb:title><sb:volume-nr>214</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>700</sb:first-page><sb:last-page>707</sb:last-page></sb:pages></sb:host><sb:comment>(discussion 707–708)</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>[10]</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Prieto</ce:surname></sb:author><sb:author><ce:given-name>K.H.</ce:given-name><ce:surname>Durflinger</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Wunderlich</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Dudley</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Enrichment of CD8<ce:sup loc="post">+</ce:sup> cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Immunother.</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>547</sb:first-page><sb:last-page>556</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>[11]</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Kobayashi</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Tanaka</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Yagi</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Minato</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tanabe</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Phase I/II study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Immunol. Immunother.</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1075</sb:first-page><sb:last-page>1084</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>[12]</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Markley</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sadelain</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>115</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>3508</sb:first-page><sb:last-page>3519</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>[13]</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.P.</ce:given-name><ce:surname>Kerkar</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Muranski</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kaiser</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Boni</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Sanchez-Perez</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Palmer</ce:surname></sb:author><sb:author><ce:given-name>R.N.</ce:given-name><ce:surname>Reger</ce:surname></sb:author><sb:author><ce:given-name>Z.A.</ce:given-name><ce:surname>Borman</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Zhang</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Morgan</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Gattinoni</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Trinchieri</ce:surname></sb:author><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tumor-specific CD8<ce:sup loc="post">+</ce:sup> T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>70</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>6725</sb:first-page><sb:last-page>6734</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>[14]</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Hsu</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Jones</ce:surname></sb:author><sb:author><ce:given-name>C.J.</ce:given-name><ce:surname>Cohen</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Zheng</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Kerstann</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Zhou</ce:surname></sb:author><sb:author><ce:given-name>P.F.</ce:given-name><ce:surname>Robbins</ce:surname></sb:author><sb:author><ce:given-name>P.D.</ce:given-name><ce:surname>Peng</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Shen</ce:surname></sb:author><sb:author><ce:given-name>T.J.</ce:given-name><ce:surname>Gomes</ce:surname></sb:author><sb:author><ce:given-name>C.E.</ce:given-name><ce:surname>Dunbar</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Munroe</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Stewart</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Cornetta</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Wangsa</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Ried</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author><sb:author><ce:given-name>R.A.</ce:given-name><ce:surname>Morgan</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cytokine-independent growth and clonal expansion of a primary human CD8<ce:sup loc="post">+</ce:sup> T-cell clone following retroviral transduction with the IL-15 gene</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>109</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>5168</sb:first-page><sb:last-page>5177</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>[15]</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.T.</ce:given-name><ce:surname>Stephan</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Moon</ce:surname></sb:author><sb:author><ce:given-name>S.H.</ce:given-name><ce:surname>Um</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Bershteyn</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Irvine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Therapeutic cell engineering with surface-conjugated synthetic nanoparticles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Med.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>1035</sb:first-page><sb:last-page>1041</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>[16]</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.T.</ce:given-name><ce:surname>Stephan</ce:surname></sb:author><sb:author><ce:given-name>S.B.</ce:given-name><ce:surname>Stephan</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Bak</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Irvine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biomaterials</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>5776</sb:first-page><sb:last-page>5787</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>[17]</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.M.</ce:given-name><ce:surname>Fahmy</ce:surname></sb:author><sb:author><ce:given-name>J.P.</ce:given-name><ce:surname>Schneck</ce:surname></sb:author><sb:author><ce:given-name>W.M.</ce:given-name><ce:surname>Saltzman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nanomedicine</sb:maintitle></sb:title><sb:volume-nr>3</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>75</sb:first-page><sb:last-page>85</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>[18]</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Tsai</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Shameli</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Yamanouchi</ce:surname></sb:author><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Clemente-Casares</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Serra</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Medarova</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Moore</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Santamaria</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Reversal of autoimmunity by boosting memory-like autoregulatory T cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Immunity</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>568</sb:first-page><sb:last-page>580</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>[19]</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Clemente-Casares</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Tsai</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Santamaria</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a “one size fits all” approach?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Mol. Med.</sb:maintitle></sb:title><sb:volume-nr>89</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>733</sb:first-page><sb:last-page>742</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>[20]</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>X.</ce:given-name><ce:surname>Wang</ce:surname></sb:author><sb:author><ce:given-name>W.C.</ce:given-name><ce:surname>Chang</ce:surname></sb:author><sb:author><ce:given-name>C.W.</ce:given-name><ce:surname>Wong</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Colcher</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Sherman</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Ostberg</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Forman</ce:surname></sb:author><sb:author><ce:given-name>S.R.</ce:given-name><ce:surname>Riddell</ce:surname></sb:author><sb:author><ce:given-name>M.C.</ce:given-name><ce:surname>Jensen</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A transgene-encoded cell surface polypeptide for selection, <ce:italic>in vivo</ce:italic> tracking, and ablation of engineered cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>118</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>1255</sb:first-page><sb:last-page>1263</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>[21]</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kalos</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Biomarkers in T cell therapy clinical trials</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Transl. Med.</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>138</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>[22]</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Minami</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Kono</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Miyazaki</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Taniguchi</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The IL-2 receptor complex: its structure, function, and target genes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Annu. Rev. Immunol.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>245</sb:first-page><sb:last-page>268</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>[23]</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Kwong</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Gai</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Elkhader</ce:surname></sb:author><sb:author><ce:given-name>K.D.</ce:given-name><ce:surname>Wittrup</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Irvine</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Localized immunotherapy <ce:italic>via</ce:italic> liposome-anchored anti-CD137<ce:hsp sp="0.25"/>+<ce:hsp sp="0.25"/>IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>73</sb:volume-nr></sb:series><sb:date>2013</sb:date></sb:issue><sb:pages><sb:first-page>1547</sb:first-page><sb:last-page>1558</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>[24]</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Baudino</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Shinohara</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Nimmerjahn</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Furukawa</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nakata</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Martinez-Soria</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Petry</ce:surname></sb:author><sb:author><ce:given-name>J.V.</ce:given-name><ce:surname>Ravetch</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Nishimura</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Izui</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Immunol.</sb:maintitle></sb:title><sb:volume-nr>181</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>6664</sb:first-page><sb:last-page>6669</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>[25]</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>W.W.</ce:given-name><ce:surname>Overwijk</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Theoret</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Finkelstein</ce:surname></sb:author><sb:author><ce:given-name>D.R.</ce:given-name><ce:surname>Surman</ce:surname></sb:author><sb:author><ce:given-name>L.A.</ce:given-name><ce:surname>de Jong</ce:surname></sb:author><sb:author><ce:given-name>F.A.</ce:given-name><ce:surname>Vyth-Dreese</ce:surname></sb:author><sb:author><ce:given-name>T.A.</ce:given-name><ce:surname>Dellemijn</ce:surname></sb:author><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Antony</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Spiess</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Palmer</ce:surname></sb:author><sb:author><ce:given-name>D.M.</ce:given-name><ce:surname>Heimann</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Klebanoff</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>L.N.</ce:given-name><ce:surname>Hwang</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Feigenbaum</ce:surname></sb:author><sb:author><ce:given-name>A.M.</ce:given-name><ce:surname>Kruisbeek</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8<ce:sup loc="post">+</ce:sup> T cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Exp. Med.</sb:maintitle></sb:title><sb:volume-nr>198</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>569</sb:first-page><sb:last-page>580</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>[26]</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Lowenthal</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Corthesy</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Tougne</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Lees</ce:surname></sb:author><sb:author><ce:given-name>H.R.</ce:given-name><ce:surname>MacDonald</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nabholz</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Immunol.</sb:maintitle></sb:title><sb:volume-nr>135</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>3988</sb:first-page><sb:last-page>3994</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>[27]</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Lowenthal</ce:surname></sb:author><sb:author><ce:given-name>R.H.</ce:given-name><ce:surname>Zubler</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nabholz</ce:surname></sb:author><sb:author><ce:given-name>H.R.</ce:given-name><ce:surname>MacDonald</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>315</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>669</sb:first-page><sb:last-page>672</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>[28]</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Kwong</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Liposome-anchored local delivery of immunomodulatory agents for tumor therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Biological Engineering</sb:maintitle></sb:title><sb:date>2012</sb:date><sb:publisher><sb:name>Massachusetts Institute of Technology</sb:name></sb:publisher></sb:edited-book></sb:host><sb:comment>(<ce:inter-ref xlink:href="http://hdl.handle.net/1721.1/76115" id="ir0010" xlink:type="simple">http://hdl.handle.net/1721.1/76115</ce:inter-ref>)</sb:comment></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>[29]</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.F.</ce:given-name><ce:surname>Murphy</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Powers</ce:surname></sb:author><sb:author><ce:given-name>C.R.</ce:given-name><ce:surname>Cantor</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Endosome pH measured in single cells by dual fluorescence flow cytometry: rapid acidification of insulin to pH 6</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>98</sb:volume-nr></sb:series><sb:date>1984</sb:date></sb:issue><sb:pages><sb:first-page>1757</sb:first-page><sb:last-page>1762</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>[30]</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Klebanoff</ce:surname></sb:author><sb:author><ce:given-name>H.T.</ce:given-name><ce:surname>Khong</ce:surname></sb:author><sb:author><ce:given-name>P.A.</ce:given-name><ce:surname>Antony</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Palmer</ce:surname></sb:author><sb:author><ce:given-name>N.P.</ce:given-name><ce:surname>Restifo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Immunol.</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>111</sb:first-page><sb:last-page>117</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>[31]</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.E.</ce:given-name><ce:surname>Dudley</ce:surname></sb:author><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Wunderlich</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Yang</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hwu</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Schwartzentruber</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Topalian</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Sherry</ce:surname></sb:author><sb:author><ce:given-name>F.M.</ce:given-name><ce:surname>Marincola</ce:surname></sb:author><sb:author><ce:given-name>S.F.</ce:given-name><ce:surname>Leitman</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Seipp</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Rogers-Freezer</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Morton</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Nahvi</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Mavroukakis</ce:surname></sb:author><sb:author><ce:given-name>D.E.</ce:given-name><ce:surname>White</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Rosenberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Immunother.</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>243</sb:first-page><sb:last-page>251</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>[32]</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.W.</ce:given-name><ce:surname>Konrad</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Hemstreet</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Hersh</ce:surname></sb:author><sb:author><ce:given-name>P.W.</ce:given-name><ce:surname>Mansell</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Mertelsmann</ce:surname></sb:author><sb:author><ce:given-name>J.E.</ce:given-name><ce:surname>Kolitz</ce:surname></sb:author><sb:author><ce:given-name>E.C.</ce:given-name><ce:surname>Bradley</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Pharmacokinetics of recombinant interleukin 2 in humans</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Res.</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>2009</sb:first-page><sb:last-page>2017</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc></originalText></full-text-retrieval-response>